Scientific Programme - 35th Annual EAU Congress (EAU20)

View programme as: Grid view List view
Print: Print
Search
Personal Planner

Sun 19 July

06:00
07:00
08:00
09:00
10:00
11:00
12:00
13:00
14:00
15:00
16:00
17:00
18:00
19:00
20:00
21:00

Grey Area, Room G105

1. 06:00
2. 07:00
3. 08:00
4. 09:00
5. 10:00
6. 11:00
7. 12:00
8. 13:00
9. 14:00
10. 15:00
11. 16:00
12. 17:00
13. 18:00
14. 19:00
15. 20:00
16. 21:00
Grey Area, Room G105
1. ESU Course 39 - Management of BPO: From medical to surgical treatment, including setbacks and operative solutions (SOS)
  
  Management of BPO: From medical to surgical treatment, including setbacks and operative solutions (SOS) ESU Course 39
  
  14:30 - 17:30
  Management of BPO: From medical to surgical treatment, including setbacks and operative solutions (SOS)
  
  ESU Course 39
  
  Sun 19 July
  14:30 - 17:30
  
  Location:
  
  Grey Area, Room G105
  
  Chair:
  
  To be confirmed
  
  Learning objectives
  
  • To help delegates understand the principles and evidence behind the assessment and medical management of a BPO patient.
  • To summarise / review the evidence base for electro surgery and lasers for surgical management of BPO.
  • To help delegates understand the factors that influence the patient’s and surgeon’s choice of treatment modalities.
  • Setbacks and Operative Solutions (SOS): Tips and Tricks to improve outcomes and avoid complications.
  
  Introduction/scene setting BPO 2020
  
  To be confirmed
  
  Assessment and medical management
  
  To be confirmed
  
  Surgical management – Electrosurgery
  
  To be confirmed
  
  Surgical management – Lasers and less invasive options
  
  To be confirmed
  
  Setbacks and operative solutions / Case presentations
  To be confirmed
  To be confirmed
  To be confirmed

06:00
07:00
08:00
09:00
10:00
11:00
12:00
13:00
14:00
15:00
16:00
17:00
18:00
19:00
20:00
21:00

Orange Area, eURO Auditorium 1
Orange Area, eURO Auditorium 2
Green Area, Room 1
Green Area, Room 2
Green Area, Room 3
Green Area, Room 4
Green Area, Room 5
Purple Area, Room Elicium 1
Purple Area, Room Elicium 2
Grey Area, RAI Auditorium
Yellow Area, Room Forum
Grey Area, Room Emerald
Yellow Area, Room E102
Yellow Area, Room E103
Green Area, Room A
Green Area, Room B
Grey Area, Room G102
Grey Area, Room G103
Grey Area, Room G104
Grey Area, Room G105
Grey Area, Room G106
Grey Area, Room G107
Grey Area, Room G108
Grey Area, Room G109
Grey Area, Room G002
Grey Area, Room G004
Orange Area, Room 1

1. 06:00
2. 07:00
3. 08:00
4. 09:00
5. 10:00
6. 11:00
7. 12:00
8. 13:00
9. 14:00
10. 15:00
11. 16:00
12. 17:00
13. 18:00
14. 19:00
15. 20:00
16. 21:00
Orange Area, eURO Auditorium 1
1. Game changing session 3 - Game changing session 3
  
  Game changing session 3 Game changing session 3
  
  07:30 - 08:00
  Game changing session 3
  
  Game changing session 3
  
  Mon 20 July
  07:30 - 08:00
  
  Location:
  
  Orange Area, eURO Auditorium 1
  
  Chairs:
  
  To be confirmed
  To be confirmed
  
  07:30 - 07:45
  
  Recurrence Risk in patients with High Grade Non-Muscle Invasive Bladder Carcinoma in the Randomised Phase III Clinical Trial ‘NIMBUS’ stratified for EORTC and CUETO risk categories. A contemporary trend to less recurrences?
  
  Speaker :
  
  M-O. Grimm, Jena (DE)
  
  Discussant :
  
  P. Black, Vancouver (CA)
  
  07:45 - 08:00
  
  Results from the phase III study of nadofaregene firadenovec: Safety and efficacy in patients (pts) with high-grade, BCG-unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC)
  
  Speaker :
  
  To be confirmed
  
  Discussant :
  
  J.A. Witjes, Nijmegen (NL)
2. Game changing session 1 - Game changing session 1
  
  Game changing session 1 Game changing session 1
  
  07:30 - 08:00
  Game changing session 1
  
  Game changing session 1
  
  Sun 19 July
  07:30 - 08:00
  
  Location:
  
  Orange Area, eURO Auditorium 1
  
  Chairs:
  
  To be confirmed
  To be confirmed
  
  07:30 - 07:45
  
  Continence following robot-assisted (R-LRPE) and conventional laparoscopic radical prostatectomy (LRPE) – results of a prospective, randomized, multicenter, patient blinded study
  
  Speaker :
  
  To be confirmed
  
  Discussant :
  
  To be confirmed
  
  07:45 - 08:00
  
  ProPSMA Study: A prospective randomised multi-centre study of PSMA-PET/CT imaging for staging high risk prostate cancer prior to curative-intent surgery or radiotherapy
  
  Speaker :
  
  To be confirmed
  
  Discussant :
  
  To be confirmed
3. Plenary session 3 - Modern prostate cancer imaging in daily practice
  
  Modern prostate cancer imaging in daily practice Plenary session 3
  
  08:00 - 10:15
  Modern prostate cancer imaging in daily practice
  
  Plenary session 3
  
  Sun 19 July
  08:00 - 10:15
  
  Location:
  
  Orange Area, eURO Auditorium 1
  
  Chairs:
  
  To be confirmed
  To be confirmed
  
  Learning objectives
  
  Imaging of prostate cancer is a rapidly changing field with many news technologies being established in the last few years. Actually true paradigm shifts were observed as image guided diagnosis of prostate cancer became a standard of care at last year’s EAU meeting. However, these new clinical pathways generate also problems and fields of uncertainty such as how to put them into context with modern biomarkers, how to apply these new pathways in the community setting, and how to make clinical benefit out of modern molecular imaging? This session addresses the most pertinent problems and issue encountered with modern imaging and gives answers how those might be overcome.
  
  08:00 - 08:15
  
  State-of-the-art lecture Ultrasound in prostate cancer imaging: Dead or ready to get started?
  
  To be confirmed
  
  08:15 - 08:35
  
  When not to biopsy? Imaging and genomics in the diagnosis of prostate cancer
  
  08:15 - 08:25
  
  Imaging as triage
  
  H.U. Ahmed, London (GB)
  
  08:25 - 08:35
  
  What might genomics add to the decision?
  
  To be confirmed
  
  08:35 - 09:05
  
  Problems with imaging in real life
  
  08:35 - 08:45
  
  MRI in the expert center vs. MRI in the community center
  
  To be confirmed
  
  08:45 - 08:55
  
  Risk stratification of prostate cancer based on targeted biopsies
  
  B.A. Hadaschik, Essen (DE)
  
  08:55 - 09:05
  
  What should you do with men you do not biopsy, or whose biopsy is negative?
  
  A. Lamb, Oxford (GB)
  
  09:05 - 09:30
  
  Debate Biochemical recurrence
  
  Moderator :
  
  N.R. Suardi, Genoa (IT)
  
  09:05 - 09:10
  
  Case presentation Biochemical recurrence after radical prostatectomy
  
  To be confirmed
  
  09:10 - 09:20
  
  Let's ask for imaging
  
  B. Tombal, Brussels (BE)
  
  09:20 - 09:30
  
  Let's start with early treatment
  
  P. Nyirády, Budapest (HU)
  
  09:30 - 10:00
  
  Case discussion Turning bright spots into meaningful action
  
  Moderator :
  
  N. Mottet, Saint-Étienne (FR)
  
  09:30 - 09:35
  
  Case presentation The biochemical recurrence patient
  
  To be confirmed
  
  09:35 - 09:42
  
  Systemic treatment
  
  To be confirmed
  
  09:42 - 09:49
  
  Metastasis-directed therapy with radiotherapy
  
  To be confirmed
  
  09:49 - 09:56
  
  Metastases-directed therapy with surgery
  
  To be confirmed
  
  09:56 - 10:00
  
  Summary from the EAU Prostate Cancer Guidelines Panel
  
  To be confirmed
  
  10:00 - 10:15
  
  State-of-the-art lecture A peek into the future: Artificial intelligence and prostate cancer imaging
  
  To be confirmed
4. Plenary session 5 - Challenges across the spectrum of bladder cancer
  
  Challenges across the spectrum of bladder cancer Plenary session 5
  
  08:00 - 10:30
  Challenges across the spectrum of bladder cancer
  
  Plenary session 5
  
  Mon 20 July
  08:00 - 10:30
  
  Location:
  
  Orange Area, eURO Auditorium 1
  
  Chairs:
  
  To be confirmed
  To be confirmed
  
  Learning objectives
  
  Clinical decision making for non muscle-invasive bladder cancer and new tools for adjuvant treatment for these tumours take a large part of this session. Furthermore an optimisation in the selection of elderly patients with advanced bladder cancer for surgical vs. conservative treatment will be presented. One part of the session deals with personalised treatment and its underlying genetic testing in bladder cancer.
  
  08:00 - 08:15
  
  State-of-the-art lecture Definition of very high-risk and refractory NMIBC
  
  To be confirmed
  
  08:15 - 08:45
  
  Debate Early cystectomy in high-risk NMIBC: A standard?
  
  08:15 - 08:25
  
  Pro
  
  To be confirmed
  
  08:25 - 08:35
  
  Con
  
  J. Palou, Barcelona (ES)
  
  08:35 - 08:45
  
  Discussion
  
  08:45 - 09:00
  
  State-of-the-art lecture Immunotherapy and beyond: New options for NMIBC
  
  P. Black, Vancouver (CA)
  
  09:00 - 09:15
  
  State-of-the-art lecture Urinary markers in low-grade NMIBC: Ready to stop cystoscopies?
  
  J.A. Witjes, Nijmegen (NL)
  
  09:15 - 09:30
  
  State-of-the-art lecture Frailty and cognitive assessment in patients diagnosed with MIBC
  
  To be confirmed
  
  09:30 - 09:45
  
  State-of-the-art lecture Treatment options for elderly patients with muscle-invasive bladder cancer
  
  M.J. Ribal Caparros, Barcelona (ES)
  
  09:45 - 10:00
  
  State-of-the-art lecture Different Bladder Cancer Genotypes: New treatment options
  
  To be confirmed
  
  10:00 - 10:15
  
  State-of-the-art lecture The future of personalised treatment: Test the tumour for a response
  
  To be confirmed
  
  10:15 - 10:30
  
  Société Internationale d’Urologie (SIU) lecture GU Tuberculosis
  
  R. Kumar, New Delhi (IN)
5. Plenary session 7 - Stones: The role of innovation
  
  Stones: The role of innovation Plenary session 7
  
  08:00 - 12:15
  Stones: The role of innovation
  
  Plenary session 7
  
  Tue 21 July
  08:00 - 12:15
  
  Location:
  
  Orange Area, eURO Auditorium 1
  
  Chairs:
  
  T. Knoll, Sindelfingen (DE)
  To be confirmed
  
  Learning objectives
  
  Today, stone treatment means endourology in most cases. New endoscopes, new lasers, new disposables promise better efficacy, lower morbidity and shorter hospital stays. Is this all true or are there potential drawbacks to be considered? Which protocols and treatment algorithms lead to the best treatment results? This plenary will give answers.
  
  08:00 - 08:15
  
  State-of-the-art lecture Temperature and intrarenal pressure during laser lithotripsy
  
  To be confirmed
  
  08:15 - 08:45
  
  Round-table discussion Perioperative Antibiotic Prophylaxis: When, how and how long?
  
  Moderator :
  
  To be confirmed
  
  08:15 - 08:22
  
  When?
  
  To be confirmed
  
  08:22 - 08:29
  
  How?
  
  To be confirmed
  
  08:29 - 08:36
  
  How long?
  
  To be confirmed
  
  08:36 - 08:45
  
  Discussion and summary
  
  To be confirmed
  
  08:45 - 09:00
  
  State-of-the-art lecture How to minimise radiation exposure in endourology
  
  A. Skolarikos, Athens (GR)
  
  09:00 - 09:20
  
  Debate New technology in retrograde intrarenal surgery: Unnecessary luxury vs. measurable benefit
  
  Moderator :
  
  To be confirmed
  
  09:00 - 09:05
  
  Measurable benefit
  
  To be confirmed
  
  09:05 - 09:10
  
  Unnecessary luxury
  
  A. Neisius, Trier (DE)
  
  09:10 - 09:20
  
  Rebuttal
  
  A. Neisius, Trier (DE)
  To be confirmed
  
  09:20 - 09:45
  
  Round-table discussion Beyond holmium laser: New lithotripsy devices
  
  Moderator :
  
  To be confirmed
  
  09:20 - 09:25
  
  Holmium
  
  K. Ghani, Ann Arbor (US)
  
  09:25 - 09:30
  
  Thulium
  
  P.M. Kronenberg, Amadora (PT)
  
  09:30 - 09:35
  
  Ballistic
  
  To be confirmed
  
  09:35 - 09:45
  
  Discussion and summary
  
  To be confirmed
  
  09:45 - 10:10
  
  Round-table discussion 1cm stone in the lower calyx plus 2cm upper ureteral stone with complete obstruction
  
  Moderator :
  
  To be confirmed
  
  09:45 - 09:50
  
  Retrograde ureteroscopy
  
  To be confirmed
  
  09:50 - 09:55
  
  Percutaneous nephrolithotomy and antegrade ureteroscopy
  
  N. Gadzhiev, Saint Petersburg (RU)
  
  09:55 - 10:00
  
  Laparoscopic ureterolithotomy and flexible nephroscopy
  
  To be confirmed
  
  10:00 - 10:10
  
  Discussion and summary
  
  To be confirmed
  
  10:10 - 10:25
  
  Confederación Americana de Urología (CAU) lecture Ureteral access sheaths: Facts and myths
  
  To be confirmed
  
  10:25 - 12:15
  
  Souvenir session
  
  10:25 - 10:45
  
  Prostate cancer and Imaging
  
  C.H. Bangma, Rotterdam (NL)
  
  10:45 - 10:55
  
  BPH/LUTS
  
  To be confirmed
  
  10:55 - 11:05
  
  Functional urology
  
  To be confirmed
  
  11:05 - 11:15
  
  Renal cancer
  
  M-O. Grimm, Jena (DE)
  
  11:15 - 11:25
  
  Bladder cancer
  
  To be confirmed
  
  11:25 - 11:35
  
  Upper Tract TCC
  
  To be confirmed
  
  11:35 - 11:45
  
  Paediatric urology
  
  To be confirmed
  
  11:45 - 11:55
  
  Stones
  
  T. Knoll, Sindelfingen (DE)
  
  11:55 - 12:05
  
  Andrology
  
  To be confirmed
  
  12:05 - 12:15
  
  Testis/Penile cancer
  
  To be confirmed
6. Plenary Session 1 - New frontiers in infections
  
  New frontiers in infections Plenary Session 1
  
  08:15 - 10:00
  New frontiers in infections
  
  Plenary Session 1
  
  Sat 18 July
  08:15 - 10:00
  
  Location:
  
  Orange Area, eURO Auditorium 1
  
  Chairs:
  
  To be confirmed
  To be confirmed
  
  Learning objectives
  
  Urological infections become more and more difficult to treat, due to the fact that on the one hand antimicrobial resistance and multiresistance emerge dramatically in causative pathogens on a global level and antibiotics are increasingly restricted. On the other hand urological patients do have more and more accompanying morbidities. This session deals with the most important and recent aspects and strategies that deal with the challenges of antimicrobial resistance, from prevention and prophylaxis to treatment of life threatening infections.
  
  08:15 - 08:30
  
  State-of-the-art lecture View on the Coronavirus crisis from a European perspective
  
  To be confirmed
  
  08:30 - 08:45
  
  State-of-the-art lecture New diagnostic techniques to overcome antibiotic resistance
  
  S. Halachmi, Haifa (IL)
  
  08:45 - 09:05
  
  How to minimise infectious complications of prostate biopsies: A white paper
  
  08:45 - 08:50
  
  Case presentation
  
  To be confirmed
  
  08:50 - 09:05
  
  State-of-the-art lecture
  
  To be confirmed
  
  09:05 - 09:20
  
  American Urological Association (AUA) lecture New insights: The impact of the microbiome on genitourinary cancer
  
  To be confirmed
  
  09:20 - 09:35
  
  State-of-the-art lecture Urosepsis: Hot data from the SERPENS study
  
  To be confirmed
  
  09:35 - 10:00
  
  Debate Infection control practices in patients at risk for multiresistant pathogens
  
  Moderator :
  
  To be confirmed
  
  09:35 - 09:45
  
  Pro isolation
  
  To be confirmed
  
  09:45 - 09:55
  
  Against isolation
  
  To be confirmed
  
  09:55 - 10:00
  
  Summary
  
  To be confirmed
7. Thematic session 19 - Radioligand therapy in metastatic castration-resistant prostate cancer
  
  Radioligand therapy in metastatic castration-resistant prostate cancer Thematic session 19
  
  10:30 - 12:00
  Radioligand therapy in metastatic castration-resistant prostate cancer
  
  Thematic session 19
  
  Sun 19 July
  10:30 - 12:00
  
  Location:
  
  Orange Area, eURO Auditorium 1
  
  Chairs:
  
  D. Murphy, Melbourne (AU)
  To be confirmed
  A. Villers, Lille (FR)
  
  Learning objectives
  
  Prostate-specific membrane antigen (PSMA) offers great potential not only as a target for diagnostic but also for therapeutic purposes. The present session highlights the application of PSMA-targeted radioligand therapy in metastatic castration-resistant prostate cancer. Indication, limitations and future developments will be discussed.
  
  10:30 - 10:45
  
  State-of-the-art lecture Current and future radioligands (ligands and emitters)
  
  M. Gauthé, Paris (FR)
  
  10:45 - 11:00
  
  State-of-the-art lecture Limitations of PSMA based on prostate cancer biology
  
  To be confirmed
  
  11:00 - 11:15
  
  State-of-the-art lecture Critical assessment of radioligand therapy
  
  To be confirmed
  
  11:15 - 11:50
  
  Case-based debate (PSMA)-targeted radioligand therapy: For which patients, which stages?
  
  Moderator :
  
  To be confirmed
  
  11:15 - 11:20
  
  Case presentation
  
  I. Tsaur, Mainz (DE)
  
  11:20 - 11:30
  
  Treatment options: Medical oncologist
  
  To be confirmed
  
  11:30 - 11:40
  
  Treatment options: Nuclear medicine
  
  M. Eiber, Munich (DE)
  
  11:40 - 11:50
  
  Radioligand therapy for less advanced cases: Urologist
  
  A. Heidenreich, Cologne (DE)
  
  11:50 - 12:00
  
  Summary and conclusion
  
  D. Murphy, Melbourne (AU)
8. Meeting of the EAU Section of Uro-Technology (ESUT), in cooperation with the EAU Robotic Urology Section (ERUS) and the EAU Section of Urolithiasis (EULIS) - Technology developments never ends!
  
  Technology developments never ends! Meeting of the EAU Section of Uro-Technology (ESUT), in cooperation with the EAU Robotic Urology Section (ERUS) and the EAU Section of Urolithiasis (EULIS)
  
  10:30 - 18:00
  Technology developments never ends!
  
  Meeting of the EAU Section of Uro-Technology (ESUT), in cooperation with the EAU Robotic Urology Section (ERUS) and the EAU Section of Urolithiasis (EULIS)
  
  Sat 18 July
  10:30 - 18:00
  
  Location:
  
  Orange Area, eURO Auditorium 1
  
  Chair:
  
  To be confirmed
9. Award winning abstract session - Award winning abstract session
  
  Award winning abstract session Award winning abstract session
  
  10:45 - 11:45
  Award winning abstract session
  
  Award winning abstract session
  
  Mon 20 July
  10:45 - 11:45
  
  Location:
  
  Orange Area, eURO Auditorium 1
  
  Chairs:
  
  P. Albers, Düsseldorf (DE)
  A. Stenzl, Tübingen (DE)
  
  10:48 - 10:59
  
  3rd prize - non-oncology 640 Increased stromal components and prostatic fibrosis via altering the CYP19/Estrogen/GPER signaling in the early progression of BPH tissues of men ≤ 50 years old
  To be confirmed
  
  Discussant :
  
  To be confirmed
  
  10:59 - 11:10
  
  2nd prize - non-oncology 285 Are glomerulations still a characteristic marker for interstitial cystitis/bladder pain syndrome? Biological evidences from global gene expression and comprehensive immunohistochemical quantification analyses
  To be confirmed
  
  Discussant :
  
  To be confirmed
  
  11:10 - 11:21
  
  1st prize - non-oncology 423 Novel model of micturition based on a multi-unit recordings of optogenetically-identified Barrington’s CRH neurons in mice
  To be confirmed
  
  Discussant :
  
  To be confirmed
  
  11:21 - 11:32
  
  2nd prize - oncology 925 Late toxicity and quality of life from GETUG-AFU 22 study: A randomized phase II trial comparing 6 months of degarelix in combination with radiotherapy to radiotherapy alone for patients with detectable PSA after radical prostatectomy
  To be confirmed
  
  Discussant :
  
  To be confirmed
  
  11:32 - 11:43
  
  1st prize - oncology PT090 Inhibition steroid sulfatase suppresses androgen signaling and improves response to enzalutamide
  To be confirmed
  
  Discussant :
  
  Z. Culig, Innsbruck (AT)
  
  11:43 - 11:45
  
  Conclusion
  P. Albers, Düsseldorf (DE)
  A. Stenzl, Tübingen (DE)
10. Video Session 07 - Evolving techniques in upper urinary tract surgery
  
  Evolving techniques in upper urinary tract surgery Video Session 07
  
  12:15 - 13:45
  Evolving techniques in upper urinary tract surgery
  
  Video Session 07
  
  Sun 19 July
  12:15 - 13:45
  
  Location:
  
  Orange Area, eURO Auditorium 1
  
  Chairs:
  
  To be confirmed
  To be confirmed
  To be confirmed
  
  All presentations have a maximum length of 8 minutes, followed by 4 minutes of discussion.
  
  12:15 - 12:18
  
  Introduction
  
  V046
  
  Patient care pathway hypnosedation in endo urology: An innovative alternative to general anesthesia
  
  To be confirmed
  
  V047
  
  Cold en bloc excision of non muscle invasive bladder cancer less than 3cm using a novel Zedd scissors: Our initial experience
  
  To be confirmed
  
  V048
  
  Percutaneous treatment of pelvis-calyceal nephrogenic adenoma: Technique description
  
  By: Melgarejo Segura M.T. , Cano-García M.C. , Garcia-Lopez C. , Jimenez-Pacheco A. , Morales-Martinez A. , Arrabal-Martin M. , Arrabal-Polo M.A.
  
  Institutes: Hospital Universitario Clinico San Cecilio, Dept. of Urology, Granada, Spain
  
  V049
  
  Testing feasibility of an accurate microscopic assessment of urological specimens by smartphone add-on lenses
  
  To be confirmed
  
  V050
  
  Dual thulium-holmium laser ablation by percutaneous approach of upper tract urinary carcinoma in a solitary kidney: An imperative case
  
  To be confirmed
  
  V051
  
  Evolving techniques of endoscopic UTUC management: Optimising outcomes with the appropriate use of latest technologies
  
  To be confirmed
  
  V052
  
  Allium ureteral stents: A critical analysis of our cases
  
  By: Sampogna G. , Albo G. , Zanetti S.P. , Rocchini L. , Fontana M. , De Lorenzis E. , Boeri L. , Gallioli A. , Longo F. , Montanari E.
  
  Institutes: Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico, University of Milan, Dept. of Urology, Milan, Italy
  
  13:38 - 13:43
  
  Closing remarks
11. Video Session 10 - Meeting the challenges of partial nephrectomy
  
  Meeting the challenges of partial nephrectomy Video Session 10
  
  12:15 - 13:45
  Meeting the challenges of partial nephrectomy
  
  Video Session 10
  
  Mon 20 July
  12:15 - 13:45
  
  Location:
  
  Orange Area, eURO Auditorium 1
  
  Chairs:
  
  To be confirmed
  A. Carbone, Latina (IT)
  To be confirmed
  
  All presentations have a maximum length of 8 minutes, followed by 4 minutes of discussion.
  
  12:15 - 12:18
  
  Introduction
  
  V068
  
  The role of Indocyanine Green (ICG) in guiding robot-assisted partial nephrectomy: A prospective multi-institutional TRONES study
  
  To be confirmed
  
  V069
  
  ICG-guided robotic-assisted partial adrenalectomy
  
  To be confirmed
  
  V070
  
  Robotic partial nephrectomy for complex hilar tumors: Tips & tricks
  
  By: Bauza Quetglas J.L. ¹ , Pieras E. ¹ , Murthy P. ² , Tubau V. ¹ , De La Cruz M. ¹ , Martínez A. ¹ , Guimerà J. ¹ , Sagalovich D. ² , Bertolo R. ² , Kaouk J. ²
  
  Institutes: ¹Son Espases University Hospital, Dept. of Urology, Palma, Spain, ²Glickman Urological & Kidney Institute - Cleveland Clinic, Center for laparoscopic and robotic surgery, Ohio, United States of America
  
  V071
  
  Preservation of vascularized cortex using virtual partial nephrectomy imaging during robot-assisted partial nephrectomy
  
  By: Izumi K. , Kawanishi Y. , Yamanaka M. , Kawanishi S. , Fukawa T. , Kanayama H.
  
  Institutes: Takamatsu Red Cross Hospital, Dept. of Urology, Takamatsu, Japan
  
  V072
  
  Rapid segmentation of renal tumours to calculate volume using 3D interpolation
  
  To be confirmed
  
  V073
  
  How far is too far? Exploring the indication for partial nephrectomy in highly complex kidney tumors
  
  To be confirmed
  
  V074
  
  Multiple partial nephrectomy for multifocal synchronous renal cancer in a solitary kidney
  
  By: Picola Brau N. ¹ , Rivero Belenchón I. ² , Mercader Barrull C. ³ , Benfante N. ⁴ , Vigués Julià F. ¹ , Apatov S. ⁴ , Russo P. ⁴ , Coleman J. ⁴ , Touijer K. ⁴
  
  Institutes: ¹Bellvitge University Hospital, Dept. of Urology, Barcelona, Spain, ²Virgen del Rocío University Hospital, Dept. of Uro-Nephrology, Seville, Spain, ³Clinic Barcelona University Hospital, Dept. of Urology, Barcelona, Spain, ⁴Memorial Sloan Kettering Cancer Center, Dept. of Urology, New York, United States of America
  
  13:34 - 13:39
  
  Closing remarks
12. Video Session 12 - Challenging kidney surgery
  
  Challenging kidney surgery Video Session 12
  
  14:00 - 15:30
  Challenging kidney surgery
  
  Video Session 12
  
  Mon 20 July
  14:00 - 15:30
  
  Location:
  
  Orange Area, eURO Auditorium 1
  
  Chairs:
  
  To be confirmed
  To be confirmed
  R.J.A. Van Moorselaar, Amsterdam (NL)
  
  All presentations have a maximum length of 8 minutes, followed by 4 minutes of discussion.
  
  14:00 - 14:03
  
  Introduction
  
  V082
  
  Pushing the limits of robotic assisted partial nephrectomy: Off-clamp approach for bilateral, hilar and totally endophytic renal masses
  
  To be confirmed
  
  V083
  
  Robot-assisted right radical nephrectomy with level II inferior vena cava tumor thrombectomy: The video demonstration
  
  By: Dev P. , Yuvaraja T.B. , Santosh W. , Pednekar A.
  
  Institutes: Kokilaben Dhirubhai Ambani Hospital, Dept. of Robotic Surgery and Uro-Oncology, Mumbai, India
  
  V084
  
  Thrombectomy and cavoraphy performed totally intracorporeal with a 3D laparoscopic approach in treating T3a and T3b renal cell carcinoma
  
  To be confirmed
  
  V085
  
  Off-clamp robot-assisted partial nephrectomy for cT2 renal cancers
  
  To be confirmed
  
  V086
  
  Renal cell carcinoma with level IV thrombosis. Radical nephrectomy without cardiopulmonary bypass: A series at our institution
  
  To be confirmed
  
  V087
  
  Robot-assisted laparoscopic cavectomy without IVC replacement for right RCC and inferior vena cava thrombus
  
  By: Olivero A. ¹ , Huang Q. ² , Fan Y. ² , Wang B. ² , Ma X. ² , Zhang X. ²
  
  Institutes: ¹San Martino Policlinico Hospital, IRCCS for Oncology, Dept. of Urology, Genova, Italy, ²Chinese PLA General Hospital/PLA Medical School, Beijing, Dept. of Urology, Beijing, China
  
  V088
  
  Imaging guided surgery with augmented reality for robotic partial nephrectomy
  
  To be confirmed
  
  15:21 - 15:26
  
  Closing remarks
13. Video Session 08 - Award winning video session
  
  Award winning video session Video Session 08
  
  14:00 - 15:30
  Award winning video session
  
  Video Session 08
  
  Sun 19 July
  14:00 - 15:30
  
  Location:
  
  Orange Area, eURO Auditorium 1
  
  Chairs:
  
  To be confirmed
  A. Messas, Paris (FR)
  To be confirmed
  
  All presentations have a maximum length of 8 minutes, followed by 4 minutes of discussion.
  
  14:00 - 14:03
  
  Introduction
  
  V053
  
  3D augmented reality robot-assisted radical prostatectomy: The computer vision algorithm allows to identify the extracapsular extension on neurovascular bundles
  
  By: Porpiglia F. ¹ , Checcucci E. ¹ , Amparore D. ¹ , Piana A. ¹ , Piramide F. ¹ , Volpi G. ¹ , De Cillis S. ¹ , Manfredi M. ¹ , Piazzolla P. ² , Fiori C. ¹ , Vezzetti E. ²
  
  Institutes: ¹AOU San Luigi Gonzaga, University of Turin, Dept. of Urology, Orbassano, Italy, ²Politecnico di Torino, Dept. of Management and Production Engineering, Turin, Italy
  
  V054
  
  Technical aspects of Robotic Assisted Laparoscopic Ureterolysis (RALU) for the treatment of ureteric obstruction from Retroperitoneal Fibrosis (RPF)
  
  To be confirmed
  
  V055
  
  The new adjustable artificial sphincter victo: Surgical technique and results after a follow-up of more than one year
  
  By: Ameli G. , Weibl P. , Rutkowski M. , Hübner W.A.
  
  Institutes: Clinic of Korneuburg, Dept. of Urology, Korneuburg, Austria
  
  V056
  
  Transperineal laser ablation of prostate
  
  To be confirmed
  
  V057
  
  Safety and short-term oncological outcomes of thulium fiber laser en-bloc resection of non-muscle-invasive bladder cancer: A prospective non-randomized phase II trial
  
  By: Enikeev D. ¹ , Taratkin M. ¹ , Laukhtina E. ¹ , Sukhanov R. ¹ , Dymov A. ¹ , Sorokin N. ² , Shariat S.F. ³ , Glybochko P. ¹
  
  Institutes: ¹Sechenov University, Institute for Urology and Reproductive Health, Moscow, Russia, ²Moscow State University, Dept. of Urology, Moscow, Russia, ³Medical University of Vienna, Dept. of Urology, Vienna, Austria
  
  V058
  
  Double-face augmentation urethroplasty for bulbar urethral strictures-dorsal versus ventral approach: Technical implications and short-term outcomes
  
  To be confirmed
  
  V059
  
  Innovations and technical variations in robot-assisted kidney transplantation: Results from the ERUS working group
  
  By: Gallioli A. ¹ , Boissier R. ¹ , Territo A. ¹ , Campi R. ² , Vignolini G. ² , Musquera M. ³ , Alcaraz A. ³ , Decaestecker K. ⁴ , Tugcu V. ⁵ , Vanacore D. ¹ , Serni S. ² , Breda A. ¹
  
  Institutes: ¹Fundacio Puigvert, Dept. of Urology, Barcelona, Spain, ²Careggi Hospital, University of Florence, Dept. of Urology, Florence, Italy, ³Hospital Clinic, Dept. of Urology, Barcelona, Spain, ⁴Ghent University Hospital, Dept. of Urology, Ghent, Belgium, ⁵Bakirkoy Dr. Sadi Konuk Training and Research Hospital, Dept. of Urology, Istanbul, Turkey
  
  15:21 - 15:26
  
  Closing remarks
14. Video Session 09 - Advanced reconstructive surgery
  
  Advanced reconstructive surgery Video Session 09
  
  15:45 - 17:15
  Advanced reconstructive surgery
  
  Video Session 09
  
  Sun 19 July
  15:45 - 17:15
  
  Location:
  
  Orange Area, eURO Auditorium 1
  
  Chairs:
  
  A. Hosseini, Stockholm (SE)
  To be confirmed
  F. Van Der Aa, Leuven (BE)
  
  All presentations have a maximum length of 8 minutes, followed by 4 minutes of discussion.
  
  15:45 - 15:48
  
  Introduction
  
  V060
  
  Robotic augmentation cystoplasty for contracted bladder secondary to cystitis: A 1-year outcome assessment
  
  By: Yee C-H. , Chiu P.K.F. , Chan S.Y.S. , Teoh J.Y.C. , Tam H.M. , Chan C.K. , Hou S.M. , Tam P.Y.H. , Ng C.F.
  
  Institutes: S.H. Ho Urology Centre, The Chinese University of Hong Kong., Dept. of Surgery, Hong Kong, Hong Kong
  
  V061
  
  Robot-assisted laparoscopic continent cutaneous urinary diversion (Mitrofanoff and Yang-Monti conduits) in a consecutive series of 8 adult patients. Surgical technique and initial outcomes: A Mitrofanoff with bladder augmentation procedure
  
  To be confirmed
  
  V062
  
  Use of Indocyanine Green (ICG) in reconstructive robotic urology: A multi-institutional study of the ERUS reconstructive scientific working group
  
  To be confirmed
  
  V063
  
  Robot-assisted laparoscopic continent cutaneaous urinary diversion (Mitrofanoff and Yang-Monti conduits) in a consecutive series of 8 adults patients: Surgical technique and initial outcomes - a Yang-Monti modified Casale procedure
  
  To be confirmed
  
  V064
  
  Totally intracorporeal robot-assisted kidney auto-transplantation
  
  By: Van Praet C. ¹ , Van Parys B. ¹ , Desender L. ² , Decaestecker K. ¹
  
  Institutes: ¹Ghent University Hospital, Dept. of Urology, Ghent, Belgium, ²Ghent University Hospital, Thoracic and Vascular Surgery, Ghent, Belgium
  
  V065
  
  Robotic ileal neoureter and psoas hitch for iatrogenic complete ureteral avulsion: Our 2 cases experience
  
  To be confirmed
  
  V066
  
  Robot-assisted tension free surgery in distal ureteral disease
  
  To be confirmed
  
  V067
  
  Robot-assisted bilateral ileal ureteral substitution of long segment ureter strictures
  
  To be confirmed
  
  17:06 - 17:10
  
  Discussion V065-V067
  
  17:10 - 17:15
  
  Closing remarks
15. Video Session 14 - Technological solutions for BPH
  
  Technological solutions for BPH Video Session 14
  
  15:45 - 17:15
  Technological solutions for BPH
  
  Video Session 14
  
  Mon 20 July
  15:45 - 17:15
  
  Location:
  
  Orange Area, eURO Auditorium 1
  
  Chairs:
  
  Y. Ahallal, Meknes (MA)
  M. Gacci, Florence (IT)
  To be confirmed
  
  All presentations have a maximum length of 8 minutes, followed by 4 minutes of discussion.
  
  15:45 - 15:48
  
  Introduction
  
  V099
  
  Minimizing post-operative stress urinary incontinence after HoLEP: Our preliminary experience and short-term results of ‘’En Bloc’’ technique with early apical release
  
  To be confirmed
  
  V100
  
  Redo en bloc HoLEP with early apical release for prostate adenomatous remnants
  
  By: Rodriguez Socarrás M. , Michel Mercado I. , Cuadros Rivera V. , Fernández Del Álamo J. , Gómez Rivas J. , Reinoso Elbers J. , Llanes González L. , Juarez Del Dago P. , Gomez Sancha F.
  
  Institutes: ICUA Clínica CEMTRO, Dept. of Urology, Madrid, Spain
  
  V101
  
  Prospective randomized study of monopolar enucleation vs transurethral resection of the prostate: Two year follow up
  
  By: Enikeev D. ¹ , Rapoport L. ¹ , Gazimiev M. ¹ , Taratkin M. ¹ , Laukhtina E. ¹ , Sung J.M. ² , Okhunov Z. ² , Glybochko P. ¹
  
  Institutes: ¹Sechenov University, Institute for Urology and Reproductive Health, Moscow, Russia, ²University of California, Dept. of Urology, Irvine, United States of America
  
  V102
  
  Laparoscopic simple prostatectomy: Description of the surgical steps and outcomes
  
  To be confirmed
  
  V103
  
  “Pretransection of urethral mucosa at the apex of prostate” holmium laser enucleation of the prostate: A modified en bloc technique for transurethral anatomic prostatectomy
  
  To be confirmed
  
  V104
  
  A novel robotic approach to treat BPH: First experience with Aquablation
  
  To be confirmed
  
  V105
  
  Efficacy of aquablation in patients with urinary retention
  
  By: Yee C-H. , Ng C.F. , Chiu P.K.F. , Wong H.F. , Yuen S.K.K. , Chan Y.S. , Teoh J.Y.C. , Tam H.M. , Chan C.K. , Hou S.M.
  
  Institutes: S.H. Ho Urology Centre, The Chinese University of Hong Kong., Dept. of Surgery, Hong Kong, Hong Kong
  
  V106
  
  Aquablation- image-guided robot-assisted waterjet ablation of the prostate: Preliminary results of a non-selected, consecutive, patients cohort of a national multicentre clinical experience
  
  By: Cocci A. ¹ , Salvi M. ¹ , Di Trapani E. ² , Musi G. ² , Cozzi G. ² , De Cobelli O. ² , Rinaldi M. ³ , Minafra P. ⁴ , De Rienzo G. ⁵ , Cimino S. ⁶ , Verze P. ⁷ , Mirone V. ⁷ , Morgera V. ⁷ , Bianchi L. ³ , Borghesi M. ³ , Guerra M. ³ , Schiavina R. ³ , Brunocilla E. ³ , Polloni G. ⁸ , Tuccio A. ¹ , Gacci M. ¹ , Serni S. ¹ , Minervini A. ¹ , Carini M. ¹ , Russo G.I. ⁶
  
  Institutes: ¹University of Florence, Dept. of Urology, Florence, Italy, ²European Institute of Oncology, Dept. of Urology, Milan, Italy, ³University of Bologna, Dept. of Urology, Bologna, Italy, ⁴Affidea Modena medica, Dept. of Urology, Modena, Italy, ⁵University of Bari, Dept. of Urology, Bari, Italy, ⁶University of Catania, Dept. of Urology, Catania, Italy, ⁷University of Naples, Dept. of Urology, Naples, Italy, ⁸Psycho-sexology, Dept. of Psycho-Sexology, Como, Italy
  
  17:04 - 17:10
  
  Discussion V104-V106
  
  17:10 - 17:15
  
  Closing remarks
16. EAU Opening Ceremony
  
  EAU Opening Ceremony
  
  18:00 - 19:30
  EAU Opening Ceremony
  
  Fri 17 July
  18:00 - 19:30
  
  Location:
  
  Orange Area, eURO Auditorium 1
  
  Opening performance
  
  Opening address
  
  C.R. Chapple, Sheffield (GB)
  
  Announcement of the new EAU Honorary Members
  
  Presentation of the EAU Willy Gregoir Medal 2020
  
  Presentation of the EAU Frans Debruyne Life Time Achievement Award 2020
  
  Presentation of the EAU Crystal Matula Award 2020
  
  Presentation of the EAU Hans Marberger Award 2020
  
  EAU Innovators in Urology Award
  
  EAU Ernest Desnos Prize
  
  Presentation of the EAU Prostate Cancer Research Award 2020
  
  Closing performance
17. Networking Reception
  
  Networking Reception
  
  19:30 - 21:00
Orange Area, eURO Auditorium 2
1. Game changing session 2 - Game changing session 2
  
  Game changing session 2 Game changing session 2
  
  07:30 - 08:00
  Game changing session 2
  
  Game changing session 2
  
  Sun 19 July
  07:30 - 08:00
  
  Location:
  
  Orange Area, eURO Auditorium 2
  
  Chairs:
  
  To be confirmed
  To be confirmed
  
  07:30 - 07:45
  
  A prospective randomized study of bicalutamide +/- docetaxel for non metastatic prostate cancer with a rising PSA (SPCG-14)
  
  Speaker :
  
  A.S. Josefsson, Göteborg (SE)
  
  Discussant :
  
  C. Sweeney, Boston (US)
  
  07:45 - 08:00
  
  Health-related quality-of-life (HRQoL) analysis from KEYNOTE-426: pembrolizumab (pembro) plus axitinib (axi) vs sunitinib for advanced renal cell carcinoma (RCC)
  
  Speaker :
  
  To be confirmed
  
  Discussant :
  
  To be confirmed
2. Game changing session 4 - Game changing session 4
  
  Game changing session 4 Game changing session 4
  
  07:45 - 08:00
  Game changing session 4
  
  Game changing session 4
  
  Mon 20 July
  07:45 - 08:00
  
  Location:
  
  Orange Area, eURO Auditorium 2
  
  Chairs:
  
  To be confirmed
  To be confirmed
  
  07:45 - 08:00
  
  The real effect of prostate cancer treatment: EUPROMS study first patient driven quality of life study ever
  
  Speaker :
  
  A. Deschamps, Antwerpen (BE)
  
  Discussant :
  
  S. Joniau, Leuven (BE)
3. Plenary session 4 - Nightmare on robotics
  
  Nightmare on robotics Plenary session 4
  
  08:00 - 10:15
  Nightmare on robotics
  
  Plenary session 4
  
  Sun 19 July
  08:00 - 10:15
  
  Location:
  
  Orange Area, eURO Auditorium 2
  
  Chairs:
  
  To be confirmed
  To be confirmed
  
  Learning objectives
  
  Bertie Leigh is back exploring and probing the complications of robotic surgery through the prism of the law court. In so doing we hope to improve approaches to consent, surgical technique and training.
  
  Scenarios 1&3 explore challenges arising from the uniqueness of robotics viz, what to do after mechanical failure and issues arising from the physical separation of surgeon and assistant. Scenario 2 explores the transition to performing highly complex robotic procedures.
  
  The session will be entertaining and challenging. “If my case came to court, how would I look?“
  
  08:00 - 08:40
  
  Case discussion Mechanical failure of the robot during RARP: Should I have stopped?
  
  08:00 - 08:05
  
  Case presentation
  
  To be confirmed
  
  08:05 - 08:15
  
  Case discussion
  
  To be confirmed
  
  08:15 - 08:35
  
  Cross-examination
  
  B. Leigh, London (GB)
  
  08:35 - 08:40
  
  Case solution and audience questions
  
  08:40 - 09:20
  
  Case discussion Were you ready for this level of complexity? Robotic T3 RCC into the IVC
  
  08:40 - 08:45
  
  Case presentation
  
  To be confirmed
  
  08:45 - 08:55
  
  Case discussion
  
  To be confirmed
  
  08:55 - 09:15
  
  Cross-examination
  
  B. Leigh, London (GB)
  
  09:15 - 09:20
  
  Case solution and audience questions
  
  09:20 - 10:00
  
  Case discussion Was your team appropriately skilled? Bowel perforation during robotic radical cystectomy
  
  09:20 - 09:25
  
  Case presentation
  
  To be confirmed
  
  09:25 - 09:35
  
  Case discussion
  
  To be confirmed
  
  09:35 - 09:55
  
  Cross-examination
  
  B. Leigh, London (GB)
  
  09:55 - 10:00
  
  Case solution and audience questions
  
  10:00 - 10:15
  
  Closing remarks
4. Plenary session 6 - Bladder dysfunction, storage symptoms and benign prostatic disease
  
  Bladder dysfunction, storage symptoms and benign prostatic disease Plenary session 6
  
  08:00 - 10:15
  Bladder dysfunction, storage symptoms and benign prostatic disease
  
  Plenary session 6
  
  Mon 20 July
  08:00 - 10:15
  
  Location:
  
  Orange Area, eURO Auditorium 2
  
  Chairs:
  
  To be confirmed
  To be confirmed
  
  Learning objectives
  
  This plenary session on male LUTS will cover the topic of bladder dysfunction especially in the context of concomitant benign prostatic obstruction. Leaders in the field will comprehensively discuss up-to-date medical and surgical solutions, recent advances in the therapies of male LUTS and current key pathophysiological concepts underlying male LUTS.
  
  08:00 - 08:10
  
  State-of-the-art lecture Pathophysiology and in depth evaluation of mixed symptoms: Beyond the I-PSS
  
  C. Gratzke, Freiburg (DE)
  
  08:10 - 08:20
  
  State-of-the-art lecture Basic neurological workup in a male LUTS patient: Keypoints for daily clinical practice
  
  To be confirmed
  
  08:20 - 08:45
  
  Crossfire Non-neurogenic OAB in a 60yr man with 60g prostate: First-line medical prescription
  
  Moderator :
  
  To be confirmed
  
  08:20 - 08:25
  
  Choose anticholinergics
  
  C. De Nunzio, Rome (IT)
  
  08:25 - 08:30
  
  Choose a Beta-3 agonist
  
  To be confirmed
  
  08:30 - 08:35
  
  Choose alpha blockers
  
  To be confirmed
  
  08:35 - 08:40
  
  Role of combination therapy
  
  To be confirmed
  
  08:40 - 08:45
  
  Wrap-up
  
  To be confirmed
  
  08:45 - 09:10
  
  Crossfire Non-neurogenic OAB and proven obstuction, drugs don't work
  
  Moderator :
  
  To be confirmed
  
  08:45 - 08:50
  
  Preference for resection
  
  To be confirmed
  
  08:50 - 08:55
  
  Preference for vaporisation
  
  M. Gacci, Florence (IT)
  
  08:55 - 09:00
  
  Preference for enucleation
  
  To be confirmed
  
  09:00 - 09:05
  
  Preference for aquablation
  
  To be confirmed
  
  09:05 - 09:10
  
  Wrap-up
  
  To be confirmed
  
  09:10 - 09:20
  
  State-of-the-art lecture Persistence of OAB symptoms after prostate surgery, despite good de-obstruction
  
  To be confirmed
  
  09:20 - 09:55
  
  Crossfire Minimally-invasive options for day case surgery
  
  Moderator :
  
  C. Gratzke, Freiburg (DE)
  
  09:20 - 09:25
  
  Urolift
  
  To be confirmed
  
  09:25 - 09:30
  
  TIND
  
  F. Porpiglia, Turin (IT)
  
  09:30 - 09:35
  
  Rezum therapy
  
  R.G. Hindley, Hook (GB)
  
  09:35 - 09:40
  
  Day case Greenlight laser vaporisation
  
  B. Pradere, Toulouse (FR)
  
  09:40 - 09:45
  
  Prostate embolisation
  
  To be confirmed
  
  09:45 - 09:55
  
  Minimally-invasive innovations: Wrap-up
  
  To be confirmed
  
  09:55 - 10:05
  
  Incontinence after prostate surgery: News from the AUA Guidelines
  
  To be confirmed
  
  10:05 - 10:15
  
  State-of-the-art lecture How to deal with isolated nocturia: Practical approach and treatment strategy
  
  To be confirmed
5. Plenary session 2 - #Testis cancer and surgical andrology
  
  #Testis cancer and surgical andrology Plenary session 2
  
  08:15 - 10:15
  #Testis cancer and surgical andrology
  
  Plenary session 2
  
  Sat 18 July
  08:15 - 10:15
  
  Location:
  
  Orange Area, eURO Auditorium 2
  
  Chairs:
  
  To be confirmed
  M. Albersen, Leuven (BE)
  
  Learning objectives
  
  After starting off this session with an update on the treatment algorithm of Peyronie’s disease and surgical aspects of genital reconstruction, the interrelationship of testicular cancer and male infertility –both arising from the testicular dysgenesis syndrome (TDS)- will be discussed. The attendee will take home a deeper insight in the molecular connection between these two diseases and the impact of one diagnosis on the management of the other. Autologous testicular tissue transplants are on the horizon and will be highlighted. MicroRNAs as biomarkers and robotic approaches of retroperitoneal masses are further topics of discussion and state-of-the art presentations will help to clarify their roles in current management.
  
  08:15 - 08:25
  
  Guidelines snapshot The current treatment algorythm for Peyronie's disease: Is there still a role for surgery?
  
  To be confirmed
  
  08:25 - 08:40
  
  State-of-the-art lecture "I wish I'd never… ": Complications and how to avoid them in male genital reconstructions
  
  To be confirmed
  
  08:40 - 08:50
  
  State-of-the-art lecture Infertility and the risk of testis cancer: New molecular connections
  
  To be confirmed
  
  08:50 - 09:05
  
  State-of-the-art lecture Autologous testicular tissue transplantation in young cancer patients: How far are we?
  
  To be confirmed
  
  09:05 - 09:15
  
  Guidelines snapshot How to manage testicular microlithiasis and CIS
  
  M. Dinkelman-Smit, Rotterdam (NL)
  
  09:15 - 09:30
  
  State-of-the-art lecture The new testis cancer biomarker miRNA 371: Ready for prime time?
  
  To be confirmed
  
  09:30 - 10:00
  
  Debate Twitter told me the robot can do it: Small retroperitoneal masses in testis cancer, what is best? Stage IIA
  
  09:30 - 09:35
  
  Case presentation
  
  To be confirmed
  
  09:35 - 09:45
  
  Open RPLND is still the gold standard
  
  To be confirmed
  
  09:45 - 09:55
  
  Robotic RPLND is safe and feasible
  
  To be confirmed
  
  09:55 - 10:00
  
  Concluding remarks and rebuttal: Was Twitter right? Can we use SoMe to better educate patients?
  
  To be confirmed
  
  10:00 - 10:15
  
  Society of Urologic Oncology (SUO) lecture How genetic profiling will change diagnosis and treatment in renal cancer
  
  To be confirmed
6. Poster Session 01 - Translation potential of innovative therapies in urothelium cancer
  
  Translation potential of innovative therapies in urothelium cancer Poster Session 01
  
  09:00 - 10:30
  Translation potential of innovative therapies in urothelium cancer
  
  Poster Session 01
  
  Fri 17 July
  09:00 - 10:30
  
  Location:
  
  Orange Area, eURO Auditorium 2
  
  Chairs:
  
  A. Necchi, Milan (IT)
  To be confirmed
  To be confirmed
  
  Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.
  
  * 1
  
  VAR2-armed CAR T-cells as an immunotherapeutic strategy for bladder cancer
  
  To be confirmed
  
  * 2
  
  The supplementary GM-CSF to neoadjuvant gemicitabine-cisplatin systemic chemotherapy plus PD-L1 blockade decrease local tumor recurrence of urothelial carcinoma after surgery via suppression of MDSCs in blood and tumor microevironment
  
  To be confirmed
  
  3
  
  Targeting myeloid-derived suppressor cells (MDSCs) with immune checkpoint inhibitors for treating cisplatin-resistant bladder cancer
  
  By: Takeyama Y. , Kato M. , Tamada S. , Azuma Y. , Shimizu Y. , Iguchi T. , Yamasaki T. , Gi M. , Wanibuchi H. , Nakatani T.
  
  Institutes: Osaka City University Graduate School of Medicine, Dept. of Urology, Osaka, Japan
  
  4
  
  Randomized phase III trial of dose-dense MVAC or GC as perioperative chemotherapy for muscle-invasive urothelial bladder cancer (MIUBC): Preliminary results of the GETUG/AFU V05 VESPER trial on toxicity and pathological responses
  
  To be confirmed
  
  5
  
  Cis-platinum induces immunity evasion demonstrated by PD-L1 expression in bladder cancer cells
  
  To be confirmed
  
  6
  
  Semaphorin 3C knockdown using an antisense oligonucleotide induces apoptosis and chemosensitizes in bladder cancer
  
  To be confirmed
  
  7
  
  Kdm6a deficiency activates inflammatory pathways, promotes M2 macrophage polarization and causes bladder cancer with p53 dysfunction
  
  To be confirmed
  
  8
  
  An internal cross-linked polymeric nanoparticle with dual sensitivity for combination therapy of muscle-invasive bladder cancer
  
  By: Zhu G.C. ¹ , Qin H.X. ¹ , Zhao X.Z. ¹ , Xu L.F. ¹ , Chen W. ¹ , Cao W.M. ¹ , Wang K.K. ² , Guo H.Q. ¹
  
  Institutes: ¹Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Dept. of Urology, Nanjing, China, ²Nantong University, Dept. of Pharmacy, Nantong, China
  
  9
  
  Effects of miR-30a-3p on autophagy and invasion in bladder cancer cell
  
  To be confirmed
  
  10
  
  Vorinostat and ixazomib cause bladder cancer apoptosis synergistically by inducing endoplasmic reticulum stress
  
  By: Sato A. , Asano T. , Okubo K.
  
  Institutes: National Defense Medical College, Dept. of Urology, Tokorozawa, Japan
  
  11
  
  Simvastatin augments anticancer activity of romidepsin in bladder cancer cells by causing AMP-activated protein kinase activation and histone acetylation
  
  By: Okubo K. , Asano T. , Sato A.
  
  Institutes: National Defense Medical College, Dept. of Urology, Tokorozawa, Japan
  
  12
  
  Ritonavir, a potent inhibitor of CYP3A4, enhances the anticancer effects of panobinostat in bladder cancer cells
  
  By: Sato A. , Asano T. , Okubo K.
  
  Institutes: National Defense Medical College, Dept. of Urology, Tokorozawa, Japan
  
  10:15 - 10:22
  
  Summary
  
  To be confirmed
7. Thematic session 11 - Female Stress Urinary Incontinence (SUI)
  
  Female Stress Urinary Incontinence (SUI) Thematic session 11
  
  10:30 - 12:00
  Female Stress Urinary Incontinence (SUI)
  
  Thematic session 11
  
  Mon 20 July
  10:30 - 12:00
  
  Location:
  
  Orange Area, eURO Auditorium 2
  
  Chairs:
  
  To be confirmed
  To be confirmed
  
  Learning objectives
  
  This thematic session will shed light on recent controversies about the use of synthetic slings in female with stress urinary incontinence. Experts will provide a complete update about this topic, discuss surgical alternatives and comprehensively review the armamentarium for stress incontinence management in the context of intrinsic sphincter deficiency.
  
  10:30 - 10:55
  
  Midurethral tapes for stress incontinence: Blessing or ban?
  
  10:30 - 10:40
  
  Do we have reasons to ban?
  
  To be confirmed
  
  10:40 - 10:50
  
  Do we have reasons to bless?
  
  E Costantini, Perugia (IT)
  
  10:50 - 10:55
  
  Discussion
  
  To be confirmed
  
  11:55 - 12:00
  
  Conclusion
  
  10:55 - 11:10
  
  Burch and pubovaginal sling: The perfect alternative for midurethral tapes?
  
  To be confirmed
  
  11:10 - 11:25
  
  What about bulking agents for stress incontinence?
  
  R. Hamid, London (GB)
  
  11:25 - 11:40
  
  AUS for stress incontinence in women
  
  To be confirmed
  
  11:40 - 11:55
  
  Developments in pharmacological treatments for SUI
  
  To be confirmed
8. Joint meeting of the EAU Section of Oncological Urology (ESOU), the EAU Robotic Urology Section (ERUS), the EAU Section of Uro-Technology (ESUT) and with the ECCO, EORTC GUCG, ESMO, ESSO, ESTRO and EUOG - Common problems in onco-urology
  
  Common problems in onco-urology Joint meeting of the EAU Section of Oncological Urology (ESOU), the EAU Robotic Urology Section (ERUS), the EAU Section of Uro-Technology (ESUT) and with the ECCO, EORTC GUCG, ESMO, ESSO, ESTRO and EUOG
  
  10:30 - 15:15
  Common problems in onco-urology
  
  Joint meeting of the EAU Section of Oncological Urology (ESOU), the EAU Robotic Urology Section (ERUS), the EAU Section of Uro-Technology (ESUT) and with the ECCO, EORTC GUCG, ESMO, ESSO, ESTRO and EUOG
  
  Sat 18 July
  10:30 - 15:15
  
  Location:
  
  Orange Area, eURO Auditorium 2
  
  Chairs:
  
  G. Giannarini, Udine (IT)
  S. Joniau, Leuven (BE)
  
  Learning objectives
  
  To promote the role of European urologists as principal caregivers in the field of Genito Urinary cancers.
  To advance care across the spectrum of GU cancers.
  To highlight scientific alliance between EAU sections and other scientific associations where borders between the roles of oncologists, radiotherapists and urologists are non-existent.
  
  10:30 - 10:35
  
  Welcome and introduction
  G. Giannarini, Udine (IT)
  S. Joniau, Leuven (BE)
  
  10:35 - 10:50
  
  The European Uro-Oncology Group (EUOG)
  
  10:35 - 10:45
  
  First-line treatment AR inhibitor in mHSPC: Optimizing staging and response monitoring
  
  To be confirmed
  
  10:45 - 10:50
  
  Discussion
  
  10:50 - 11:00
  
  Neo adjuvant or adjuvant chemotherapy in upper urinary tract cancer?
  
  J. Palou, Barcelona (ES)
  
  11:00 - 11:15
  
  The European Cancer Organisation (ECCO)
  
  11:00 - 11:10
  
  ECCO amplifiying the work of its member societies in EU policy and advocacy
  
  To be confirmed
  
  11:10 - 11:15
  
  Discussion
  
  11:15 - 11:30
  
  The European Society for Radiotherapy & Oncology (ESTRO)
  
  11:15 - 11:25
  
  Salvage treatment after failure of radiotherapy in localised prostate cancer
  
  To be confirmed
  
  11:25 - 11:30
  
  Discussion
  
  11:30 - 11:45
  
  The European Society for Medical Oncology (ESMO)
  
  11:30 - 11:40
  
  Current landscape of first-line systemic treatment in metastatic renal cell carcinoma
  
  L. Albiges, Villejuif (FR)
  
  11:40 - 11:45
  
  Discussion
  
  11:45 - 12:00
  
  The European Organisation for Research and Treatment of Cancer Genito-Urinary Cancer Group (EORTC GUCG)
  
  11:45 - 11:55
  
  Influence of the intake of statin on the outcome of prostate cancer
  
  To be confirmed
  
  11:55 - 12:00
  
  Discussion
  
  12:00 - 12:15
  
  The European Society of Surgical Oncology (ESSO)
  
  12:00 - 12:10
  
  Lymph node management in penile cancer: Controversies and developments
  
  M. Albersen, Leuven (BE)
  
  12:10 - 12:15
  
  Discussion
  
  12:15 - 12:25
  
  The European Association of Urology Nurses (EAUN): The follow up of renal cell cancer by the ANP in relation to the quality of care and efficiency of care
  
  To be confirmed
  
  12:25 - 15:05
  
  ESOU-ESUT-ERUS: Evidence-based case debates and controversies in onco-urology
  
  Moderators :
  
  A.E. Canda, Istanbul (TR)
  
  To be confirmed
  
  To be confirmed
  
  12:25 - 12:45
  
  Debate The role of robotic surgery: Is there still room for training young surgeons to open surgery in 2019?
  
  Pro :
  
  To be confirmed
  
  Con :
  
  To be confirmed
  
  12:45 - 13:10
  
  Debate Do we have to recommend the robotic approach systematically to perform a partial nephrectomy?
  
  Case presenter :
  
  R. Campi, Florence (IT)
  
  Pro :
  
  To be confirmed
  
  Con :
  
  G. Giannarini, Udine (IT)
  
  13:10 - 13:20
  
  Questions and answers
  
  13:20 - 13:45
  
  Debate The medico legal standpoint: A renal biopsy is mandatory in any renal cell carcinoma
  
  Case presenter :
  
  R. Campi, Florence (IT)
  
  Pro :
  
  To be confirmed
  
  Con :
  
  To be confirmed
  
  13:45 - 13:55
  
  Questions and answers
  
  13:55 - 14:20
  
  Debate Is there a right timing for molecular imaging in castration resistant prostate cancer?
  
  Case presenter :
  
  To be confirmed
  
  Pro :
  
  To be confirmed
  
  Con :
  
  To be confirmed
  
  14:20 - 14:30
  
  Questions and answers
  
  14:30 - 14:55
  
  Debate There is no role for radical cystectomy in cT0 after neodjuvant chemotherapy
  
  Case presenter :
  
  To be confirmed
  
  Pro :
  
  N. Mottet, Saint-Étienne (FR)
  
  Con :
  
  To be confirmed
  
  14:55 - 15:05
  
  Discussion
  
  15:05 - 15:10
  
  Closing remarks
  
  To be confirmed
9. Specialty Session - European Urology - Treatment of small renal masses
  
  Treatment of small renal masses Specialty Session - European Urology
  
  10:30 - 12:30
  Treatment of small renal masses
  
  Specialty Session - European Urology
  
  Sun 19 July
  10:30 - 12:30
  
  Location:
  
  Orange Area, eURO Auditorium 2
  
  Chairs:
  
  U. Capitanio, Milan (IT)
  To be confirmed
  
  Learning objectives
  
  The Surgery-in-Motion session is dedicated to the latest treatment strategies in small renal masses. Experts in the field will provide explanations and video demonstrations of various surgical techniques and discuss why they do it “their way”. Questions from the audience are welcome.
  
  10:30 - 11:29
  
  Alternative management to surgery
  
  10:30 - 10:45
  
  Active surveillance and indications for renal biopsy
  
  U. Capitanio, Milan (IT)
  
  10:45 - 10:48
  
  Discussion
  
  10:48 - 11:08
  
  Ablation, RFA and cryotherapy
  
  To be confirmed
  
  11:08 - 11:11
  
  Discussion
  
  11:11 - 11:26
  
  Other (HIFU, cyberknife, …)
  
  To be confirmed
  
  11:26 - 11:29
  
  Discussion
  
  11:29 - 12:29
  
  RAPN step-by-step
  
  11:29 - 11:41
  
  Resection techniques: Enucleation, enucleoresection, partial nephrectomy
  
  To be confirmed
  
  11:41 - 11:44
  
  Discussion
  
  11:44 - 11:56
  
  Closure techniques: Inner renorrhaphy, outer renorrhaphy, alternative methods
  
  To be confirmed
  
  11:56 - 11:59
  
  Discussion
  
  11:59 - 12:11
  
  Imaging techniques: Ultrasound, 3D imaging, augmented reality, …
  
  F. Porpiglia, Turin (IT)
  
  12:11 - 12:14
  
  Discussion
  
  12:14 - 12:19
  
  Extreme indications: Intrarenal tumour
  
  To be confirmed
  
  12:19 - 12:24
  
  Extreme indications: Big mass
  
  To be confirmed
  
  12:24 - 12:29
  
  Extreme indications: Cystic mass
  
  F. Porpiglia, Turin (IT)
  
  12:29 - 12:30
  
  Closing remarks
10. Poster Session 06 - Biomarkers in urothelium cancer and adjacent stroma
  
  Biomarkers in urothelium cancer and adjacent stroma Poster Session 06
  
  10:45 - 12:15
  Biomarkers in urothelium cancer and adjacent stroma
  
  Poster Session 06
  
  Fri 17 July
  10:45 - 12:15
  
  Location:
  
  Orange Area, eURO Auditorium 2
  
  Chairs:
  
  To be confirmed
  To be confirmed
  E. Xylinas, Paris (FR)
  
  Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.
  
  * 66
  
  Impact of molecular subtyping and immune infiltration on response and outcome following neoadjuvant pembrolizumab (pembro), versus neoadjuvant chemotherapy (NAC), in muscle-invasive bladder cancer
  
  By: Necchi A. ¹ , Raggi D. ¹ , Briganti A. ² , Farè E. ¹ , Giannatempo P. ¹ , Marandino L. ¹ , Gallina A. ² , Colecchia M. ¹ , Lucianò R. ² , Bianchi M. ² , Colombo R. ² , Salonia A. ² , Gandaglia G. ² , Fossati N. ² , Capitanio U. ² , Montorsi F. ² , Boormans J. ³ , Liu Y. ⁴ , De Jong J. ³ , Dittamore R. ⁴ , Davicioni E. ⁴ , Black P. ⁵ , Gibb E. ⁴
  
  Institutes: ¹Fondazione IRCCS Istituto Nazionale dei Tumori, Dept. of Medical Oncology, Milan, Italy, ²IRCCS San Raffaele Hospital, Dept. of Urology, Milan, Italy, ³Erasmus MC Cancer Institute, Dept. of Urology, Rotterdam, The Netherlands, ⁴Decipher Biosciences, Decipher Biosciences, Vancouver, Canada, ⁵University of British Columbia, Dept. of Urology, Vancouver, Canada
  
  67
  
  Withdrawn
  
  * 68
  
  The role of adipocytokines and their receptors in bladder cancer: Expression of adiponectin or leptin is an independent prognosticator
  
  By: Kashiwagi E. ¹ , Abe T. ¹ , Ushijima M. ¹ , Shiota M. ¹ , Netto G. ² , Eto M. ¹ , Miyamoto H. ³
  
  Institutes: ¹Kyushu University, Dept. of Urology, Fukuoka, Japan, ²Johns Hopkins University, Dept. of Pathology, Baltimore, United States of America, ³University of Rochester Medical Center, Depts. of Pathology & Laboratory Medicine, Rochester, United States of America
  
  69
  
  Impact of neoadjuvant chemotherapy on Ki67 proliferation index and PDL1 expression in muscle-invasive bladder cancer
  
  To be confirmed
  
  70
  
  SERPINB2 expression in bladder cancer is associated with cancer stem-cell like properties
  
  To be confirmed
  
  71
  
  Prediction of metastatic relapse and therapeutic response in muscle-invasive bladder cancer patients by liquid biopsy
  
  To be confirmed
  
  * 72
  
  Identifying changes in the tumor micro-environment in muscle-invasive bladder cancer after neo-adjuvant chemotherapy
  
  To be confirmed
  
  73
  
  Concordance of plasmatic circulating DNA and matched metastatic tissue in metastatic urothelial carcinoma
  
  To be confirmed
  
  74
  
  Identifying immune-related biomarkers to predict clinical outcomes of neoadjuvant immuno-chemotherapy (nivolumab, gemcitabine and cisplatin) in muscle-invasive bladder cancer (NCT03294304)
  
  By: Eckstein M. ¹ , Konety B. ² , Weight C. ² , Sonpavde G. ³ , Gupta S. ⁴ , Maughan B. ⁴ , Gibb E. ⁵ , Davicioni E. ⁵ , Paari M. ⁶ , Thyagarajan B. ⁶ , Neeraj A. ⁴ , Gupta S. ⁷
  
  Institutes: ¹Friedrich-Alexander-Universität Erlangen-Nürnberg, Institute of Pathology, Erlangen, Germany, ²University of Minnesota, Dept. of Urology, Minneapolis, United States of America, ³Harvard Medical School, Dana-Farber Cancer Institute, Boston, United States of America, ⁴University of Utah, Huntsman Cancer Institute, Salt Lake City, United States of America, ⁵GenomeDX Biosciences, Bladder Cancer Field, Vancouver, Canada, ⁶University of Minnesota, Dept. of Lab Medicine and Pathology, Minneapolis, United States of America, ⁷Cleveland Clinic, Taussig Cancer Institute, Cleveland, United States of America
  
  75
  
  Amplification of 7p12 is associated with pathologic non-response to neoadjuvant chemotherapy in muscle-invasive bladder cancer
  
  By: Pichler R. ¹ , Lindner A.K. ¹ , Compérat E. ² , Obrist P. ³ , Schäfer G. ⁴ , Todenhöfer T. ⁵ , Horninger W. ¹ , Zoran C. ¹ , Untergasser G. ⁶
  
  Institutes: ¹Medical University Innsbruck, Dept. of Urology and Andrology, Innsbruck, Austria, ²Sorbonne University, Dept. of Anatomie-Pathologique Hôpital Tenon HUEP, Paris, France, ³Pathology Laboratory Obrist and Brunhuber, Dept. of Pathology, Zams, Austria, ⁴Medical University Innsbruck, Dept. of Pathology, Innsbruck, Austria, ⁵Eberhard Karls University, Dept. of Urology, Tübingen, Germany, ⁶Medical University Innsbruck, Dept. of Internal Medicine V, Innsbruck, Austria
  
  76
  
  Exosomal transfer of HNRNPL promotes normal fibroblasts to cancer-associated fibroblasts transition in bladder cancer
  
  To be confirmed
  
  1055
  
  Bladder cancer cell proliferation is inhibited by radiofrequency treatment alone and combined with hyperthermia and chemotherapeutic agents in vitro
  
  To be confirmed
  
  1146
  
  Combination of platelet and neutrophil to lymphocyte ratio as an independent factor for overall and cancer specific survival after radical cystectomy. A multicentric retrospective cohort
  
  By: Sánchez Pérez M. ¹ , Jiménez Marrero P. ¹ , Amador Robayna A. ² , Hernández Escobar S. ¹ , Espino Espino R. ¹ , Moreno Guerra L. ¹ , Marrero Domínguez R. ¹
  
  Institutes: ¹Hospital Universitario de Gran Canaria Dr. Negrín, Dept. of Urology, Las Palmas de Gran Canaria, Spain, ²Hospital Universitario Nuestra Señora de Candelaria, Dept. of Urology, Santa Cruz de Tenerife, Spain
  
  12:06 - 12:13
  
  Summary
  
  To be confirmed
11. Poster Session 60 - Surgical BPO relief: All about enucleation
  
  Surgical BPO relief: All about enucleation Poster Session 60
  
  12:15 - 13:45
  Surgical BPO relief: All about enucleation
  
  Poster Session 60
  
  Mon 20 July
  12:15 - 13:45
  
  Location:
  
  Orange Area, eURO Auditorium 2
  
  Chairs:
  
  To be confirmed
  F. Gomez Sancha, Madrid (ES)
  To be confirmed
  
  Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.
  
  820
  
  Randomized trial of bipolar resection vs. Holmium laser enucleation vs. Greenlight laser vapo-enucleation of the prostate for treatment of large sized benign prostate obstruction; 3-years outcome
  
  To be confirmed
  
  821
  
  A prospective randomized study compares the safety and efficacy of Holmium laser enucleation of prostate versus bipolar transuretheral resection of prostate for management of benign prostatic enlargement
  
  To be confirmed
  
  822
  
  Do postoperative benefits continue after 10 years from Holmium Laser Enucleation of the Prostate (HoLEP)?
  
  By: Fallara G. ¹ , Capogrosso P. ¹ , Candela L. ¹ , Schifano N. ¹ , Pellegrino F. ¹ , Cazzaniga W. ¹ , Boeri L. ² , Belladelli F. ¹ , Dehò F. ¹ , Matloob R. ¹ , Mirone V. ³ , Salonia A. ¹ , Montorsi F. ¹
  
  Institutes: ¹IRCCS Ospedale San Raffaele, Dept. of Urology, Milan, Italy, ²IRCCS Fondazione Ca’ Granda – Ospedale Maggiore Policlinico, University of Milan, Dept. of Urology, Milan, Italy, ³Università Federico II, Dept. of Urology, Naples, Italy
  
  823
  
  The effect of laser energy consumption on the lower urinary tract symptoms in early stage after HoLEP
  
  To be confirmed
  
  824
  
  HoLEP with MOSES technology, evaluation of safety and effectiveness in a prospective randomized study on a cohort of 140 patient
  
  To be confirmed
  
  825
  
  Anterior prostatic urethral mucosa preservation technique in one-lobe enucleation HoLEP has a potential to reduce post-surgical incontinence
  
  To be confirmed
  
  826
  
  The novel HoLEP technique Omega Sign improves continence outcomes of surgery
  
  By: Tunc L. ¹ , Yalcin S. ² , Kaya E. ² , Gazel E. ³ , Yilmaz S. ² , Aybal H.C. ⁴ , Yilmaz M. ⁵ , Tokas T. ⁶
  
  Institutes: ¹Gazi University School of Medicine, Dept. of Urology, Ankara, Turkey, ²Health Sciences University,Gülhane Training and Research Hospital, Dept. of Urology, Ankara, Turkey, ³Acıbadem University Ankara Hospital, Dept. of Urology, Ankara, Turkey, ⁴Health Sciences University, Dr.Abdurrahman Yurtaslan Oncology Training and Research Hospital, Dept. of Urology, Ankara, Turkey, ⁵Health Sciences University Ankara City Hospital, Dept. of Urology, Ankara, Turkey, ⁶General Hospital Hall i.T, Dept. of Urology and Andrology, Hall in Tirol, Austria
  
  * 827
  
  Recovery from transient urinary incontinence post-HoLEP – findings from a prospective trial (ExpHo)
  
  By: Capogrosso P. ¹ , Schifano N. ¹ , Pellegrino F. ¹ , Candela L. ¹ , Fallara G. ¹ , Sorce G. ¹ , Cazzaniga W. ¹ , Matloob R. ¹ , Boeri L. ² , Deho' F. ¹ , Abate C. ¹ , Mirone V ³ , Salonia A. ¹ , Montorsi F. ¹
  
  Institutes: ¹IRCCS Ospedale San Raffaele, Dept. of Urology, Milan, Italy, ²IRCCS Fondazione Ca’ Granda – Ospedale Maggiore Policlinico, University of Milan, Dept. of Urology, Milan, Italy, ³University , Dept. of Urology, Naples, Italy
  
  828
  
  Does 5-alpha reductase inhibitor intake impact procedural efficacy, short- and long- term functional outcomes in patients undergoing Holmium Laser Enucleation of the Prostate (HoLEP)? A retrospective single-center analysis among 1,360 patients
  
  To be confirmed
  
  829
  
  Does anaesthetic technique (spinal block vs. general anesthesia) impact procedural efficacy and functional outcomes in patients undergoing Holmium Laser Enucleation of the Prostate (HoLEP)? A retrospective single-center analysis among 1,159 patients
  
  To be confirmed
  
  830
  
  HoLEP in men with catheter dependent urinary retention: Does early surgical intervention result in better outcomes?
  
  To be confirmed
  
  831
  
  A prospective, randomizised clinical trial comparing holmium laser enucleation versus photoselective vaporization for day-surgery to treat benign prostatic hyperplasia
  
  To be confirmed
  
  832
  
  Evolution of day-case HoLEP success rate over time
  
  To be confirmed
  
  833
  
  Definition of a structured training curriculum for holmium laser enucleation of the prostate
  
  To be confirmed
12. Special session - Controversies in Bladder Cancer 2020: Rapid fire debates
  
  Controversies in Bladder Cancer 2020: Rapid fire debates Special session
  
  12:45 - 15:45
  Controversies in Bladder Cancer 2020: Rapid fire debates
  
  Special session
  
  Fri 17 July
  12:45 - 15:45
  
  Location:
  
  Orange Area, eURO Auditorium 2
  
  Chairs:
  
  A.M. Kamat, Houston (US)
  A. Stenzl, Tübingen (DE)
  
  Learning objectives
  
  - Using case based discussions, allow the presenters an opportunity to discuss nuances of common dilemmas facing urologic oncology patients and providers
  - Use evidence based debates to provide clear, rationale guidance on the management of difficult situations in bladder cancer
  
  12:45 - 12:48
  
  Session introduction
  
  A.M. Kamat, Houston (US)
  
  12:48 - 13:10
  
  Rapid fire debate: Patients with NMIBC need lifelong follow-up
  
  12:48 - 12:50
  
  Case presenter
  
  A.R. Zlotta, Toronto (CA)
  
  12:50 - 13:00
  
  Discussants
  
  Pro :
  
  To be confirmed
  
  Con :
  
  To be confirmed
  
  13:00 - 13:03
  
  Summary
  
  A.R. Zlotta, Toronto (CA)
  
  13:03 - 13:10
  
  Questions and answers
  
  13:10 - 13:32
  
  Rapid fire debate: Elderly patient with recurrent TaLG tumors, small size, negative cytology
  
  13:10 - 13:12
  
  Case presenter
  
  To be confirmed
  
  13:12 - 13:17
  
  Discussant: TURBT + Intravesical therapy
  
  To be confirmed
  
  13:17 - 13:22
  
  Discussant: Active surveillance + Fulguration
  
  To be confirmed
  
  13:22 - 13:25
  
  Summary
  
  To be confirmed
  
  13:25 - 13:32
  
  Questions and answers
  
  13:32 - 13:54
  
  Rapid fire debate: Ileal conduit or continent diversion; which is a better choice for patient with GFR ~ 60
  
  13:32 - 13:34
  
  Case presenter
  
  P. Black, Vancouver (CA)
  
  13:34 - 13:39
  
  Discussant: Conduit
  
  To be confirmed
  
  13:39 - 13:44
  
  Discussant: Neobladder
  
  To be confirmed
  
  13:44 - 13:47
  
  Summary
  
  P. Black, Vancouver (CA)
  
  13:47 - 13:54
  
  Questions and answers
  
  13:54 - 14:16
  
  Rapid fire debate: Patient with pure UC, T2 disease, PDL1-high, GFR 54; seeking radical cystectomy. What is best option prior to radical cystectomy?
  
  13:54 - 13:55
  
  Case presenter
  
  To be confirmed
  
  13:55 - 13:59
  
  Discussant: Anti-PD-1 therapy
  
  A. Necchi, Milan (IT)
  
  13:59 - 14:03
  
  Discussant: Platinum based chemotherapy
  
  To be confirmed
  
  14:03 - 14:07
  
  Discussant: Upfront radical cystectomy
  
  To be confirmed
  
  14:07 - 14:09
  
  Summary
  
  To be confirmed
  
  14:09 - 14:16
  
  Questions and answers
  
  14:16 - 14:38
  
  Rapid fire debate: Otherwise healthy patient with T1HG disease plus CIS; what is the best treatment?
  
  14:16 - 14:18
  
  Case presenter
  
  To be confirmed
  
  14:18 - 14:23
  
  Discussant: Intravesical therapy
  
  J. Palou, Barcelona (ES)
  
  14:23 - 14:28
  
  Discussant: Upfront radical cystectomy
  
  J.A. Witjes, Nijmegen (NL)
  
  14:28 - 14:31
  
  Summary
  
  To be confirmed
  
  14:31 - 14:38
  
  Questions and answers
  
  14:38 - 15:00
  
  Rapid fire debate: Optimal therapy for patient with T2 disease, located at dome of bladder after neoadjuvant chemotherapy
  
  14:38 - 14:39
  
  Case presenter
  
  To be confirmed
  
  14:39 - 14:43
  
  Discussant: Radical cystectomy
  
  K. Pohar, Columbus, Ohio (US)
  
  14:43 - 14:47
  
  Discussant: ChemoXRT
  
  N. James, Sutton (GB)
  
  14:47 - 14:51
  
  Discussant: Partial cystectomy
  
  P. Gontero, Turin (IT)
  
  14:51 - 14:53
  
  Summary
  
  To be confirmed
  
  14:53 - 15:00
  
  Questions and answers
  
  15:00 - 15:22
  
  Rapid fire Debate: Otherwise healthy patient scheduled for radical cystectomy, what will have greater impact on recovery after radical cystectomy?
  
  15:00 - 15:02
  
  Case presenter
  
  To be confirmed
  
  15:02 - 15:07
  
  Discussant: ERAS
  
  To be confirmed
  
  15:07 - 15:12
  
  Discussant: Robot RC
  
  N. Navai, Houston (US)
  
  15:12 - 15:15
  
  Summary
  
  To be confirmed
  
  15:15 - 15:22
  
  Questions and answers
  
  15:22 - 15:44
  
  Rapid fire debate: 52 yr old female patient, with partial response in retroperitoneal lymph nodes after 6 cycles of platinum based chemotherapy
  
  15:22 - 15:24
  
  Case presenter
  
  To be confirmed
  
  15:24 - 15:29
  
  Discussant: Cystectomy plus RPLND
  
  S. Lerner, Houston (US)
  
  15:29 - 15:34
  
  Discussant: Alternative systemic therapy
  
  T. Powles, London (GB)
  
  15:34 - 15:37
  
  Summary
  
  To be confirmed
  
  15:37 - 15:44
  
  Questions and answers
  
  15:44 - 15:45
  
  Closing remarks
  
  A. Stenzl, Tübingen (DE)
13. Special session - Robotics in urology: Fifteen years of clinical and economic impact, and what’s next
  
  Robotics in urology: Fifteen years of clinical and economic impact, and what’s next Special session
  
  14:00 - 15:30
  Robotics in urology: Fifteen years of clinical and economic impact, and what’s next
  
  Special session
  
  Sun 19 July
  14:00 - 15:30
  
  Location:
  
  Orange Area, eURO Auditorium 2
  
  Chair:
  
  To be confirmed
  
  Learning objectives
  
  Training on a robotic surgical system fifteen years ago was an exciting new adventure for the three urologic surgeons who will speak at this symposium. At that time, there were far fewer surgeons who believed in the value of robotics or even knew much about its potential benefits.
  
  Don’t miss this opportunity to hear about their in-depth experiences from over fifteen years with robotic surgeries, their journeys, and their take on the future of robotic assisted surgery. Each surgeon will focus on one procedure area and share data on the clinical and economic impact, video surgical tips, and advantages of adopting robotics into their practices.
  
  14:00 - 14:30
  
  Nephrectomy
  
  To be confirmed
  
  14:30 - 15:00
  
  Prostatectomy
  
  To be confirmed
  
  15:00 - 15:30
  
  Cystectomy
  
  To be confirmed
14. Poster Session 70 - Non-neurogenic voiding dysfunction: Better understanding for better treatment
  
  Non-neurogenic voiding dysfunction: Better understanding for better treatment Poster Session 70
  
  14:00 - 15:30
  Non-neurogenic voiding dysfunction: Better understanding for better treatment
  
  Poster Session 70
  
  Mon 20 July
  14:00 - 15:30
  
  Location:
  
  Orange Area, eURO Auditorium 2
  
  Chairs:
  
  To be confirmed
  To be confirmed
  To be confirmed
  
  Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.
  
  967
  
  What are useful signs to differentiate detrusor underactivity from bladder outlet obstruction in men with non-neurogenic lower urinary tract symptoms?
  
  By: Matsukawa Y. , Majima T. , Funahashi Y. , Ishida S. , Naito Y. , Kato M. , Yamamoto T. , Gotoh M.
  
  Institutes: Nagoya University Graduate School of Medicine, Dept. of Urology, Nagoya, Japan
  
  968
  
  How do we diagnose detrusor underactivity? The potential of parameters calculated with Watts factor
  
  By: Kitta T. , Chiba H.C. , Higuchi M.H. , Ouchi M.O. , Togo M.T. , Takahashi Y.T. , Shinohara N.
  
  Institutes: Hokkaido University, Dept. of Urology, Sapporo, Japan
  
  969
  
  Should detrusor under activity preclude the decision of a prostatic de-obstructive surgery in men with chronic urinary retention?
  
  To be confirmed
  
  970
  
  Assessment of bladder contractility in patients with benign prostate hyperplasia using invasive and non invasive urodynamics
  
  To be confirmed
  
  971
  
  Bladder neck sparing surgery for male LUTD or not? Subtyping of bladder outflow obstruction
  
  By: Rosier P.
  
  Institutes: University Medical Center Utrecht, Dept. of Urology, Utrecht, The Netherlands
  
  972
  
  Successful trial without catheter development of a clinical nomogram
  
  By: De Nunzio C. ¹ , Tema G. ¹ , Cindolo L. ² , Bada M. ² , Lombardo R. ¹ , Nacchia A. ¹ , Cancrini F. ¹ , Voglino O.A. ¹ , Mancini E. ¹ , Guarnotta G. ¹ , Schips L. ³ , Gacci M. ⁴ , Milanesi M. ⁴ , Cito G. ⁴ , Serni S. ⁴ , Tubaro A. ¹
  
  Institutes: ¹Sant'Andrea Hospital, Dept. of Urology, Rome, Italy, ²S. Pio da Pietrelcina Hospital, Dept. of Urology, Vasto, Italy, ³S. Pio Hospital da Pietrelcina, Dept. of Urology, Vasto, Italy, ⁴Careggi Hospital, Dept. of Urology, Florence, Italy
  
  973
  
  Voiding dysfunction and sacral nerve stimulation in men: A ten year follow up review
  
  To be confirmed
  
  974
  
  Sacral neuromodulation and non-obstructive retention: Monocentric retrospective study
  
  To be confirmed
  
  975
  
  Third sacral foramen morphometry analysis in Chinese and lead implantation for sacral neuromodulation
  
  To be confirmed
  
  976
  
  Clinical outcomes of sacral neuromodulation in non-neurogenic, non-obstructive dysuria: A retrospective, multicentre study in China
  
  By: Meng L. ¹ , Wei Z. ¹ , Jianye W. ¹ , Yaoguang Z. ¹ , Peng Z. ² , Limin L. ³ , Jianwei L. ⁴ , Qing L. ⁵ , Zhongqing W. ⁶ , Tie Z. ⁷ , Zhihui X. ⁸ , Wen W. ⁹ , Jiayi L. ⁴ , Deyi L. ¹⁰
  
  Institutes: ¹Beijing Hospital, Dept. of Urology, Beijing, China, ²Beijing Chaoyang Hospital, Dept. of Urology, Beijing, China, ³China Rehabilitation Research Centre, Dept. of Urology, Beijing, China, ⁴Renji Hospital, Shanghai Jiao Tong University School of Medicine, Dept. of Urology, Shanghai, China, ⁵Tongji Hospital, Huazhong University of Science and Technology, Dept. of Urology, Wuhan, China, ⁶The Second Affiliated Hospital of Nanjing Medical University, Dept. of Urology, Nanjing, China, ⁷The Second Affiliated Hospital of Xi’an Jiaotong University, Dept. of Urology, Xi'an, China, ⁸Zhejiang Provincial People’s Hospital, Dept. of Urology, Hangzhou, China, ⁹Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Dept. of Urology, Shanghai, China, ¹⁰West China Hospital, Sichuan University, Dept. of Urology, Chengdu, China
  
  977
  
  Cardio-thoracic ratio (CTR) is associated with severe nocturia in men
  
  To be confirmed
  
  978
  
  Association between male nocturia and smoking exposure: Does smoking cessation improve nocturia?
  
  To be confirmed
  
  979
  
  Nocturnal hesitancy is a bothersome symptom we cannot ignore
  
  To be confirmed
  
  980
  
  Post micturition dribble is a highly bothersome urinary symptom: Sub analysis from the urodynamics for prostate surgery trial; randomised evaluation of assessment methods (upstream) study
  
  To be confirmed
  
  981
  
  Withdrawn
15. Poster Session 79 - Female urology miscellaneous
  
  Female urology miscellaneous Poster Session 79
  
  15:45 - 17:15
  Female urology miscellaneous
  
  Poster Session 79
  
  Mon 20 July
  15:45 - 17:15
  
  Location:
  
  Orange Area, eURO Auditorium 2
  
  Chairs:
  
  To be confirmed
  To be confirmed
  E Costantini, Perugia (IT)
  
  Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.
  
  1078
  
  Complications after perineal surgery (with or without implantation of material): First results of the French multicenter observatory VIGIMESH after 1873 inclusions
  
  To be confirmed
  
  1079
  
  Urinary incontinence in community dwelling Australian adults aged 70 years and above: Prevalence and causal associations
  
  By: Cheng J. ¹ , Simons K. ² , Crozier J. ¹ , Liew D. ³ , McNeil J. ³ , O'Connell H. ¹ , ASPREE
  
  Institutes: ¹Western Health, Dept. of Urology, Melbourne, Australia, ²Melbourne University, School of Population and Global Health, Melbourne, Australia, ³Monash University, School of Public Health and Preventive Medicine, Melbourne, Australia
  
  1080
  
  Total versus subtotal hysterectomy associated with laparoscopic colposacropexy: A prospective randomized controlled trial
  
  To be confirmed
  
  1081
  
  Sexual dysfunction in adult women with spina bifida
  
  To be confirmed
  
  1082
  
  Sexual function outcomes in patients and patients’ spouses after midurethral sling procedure for stress urinary incontinence: Data from a minimum of 6 years of follow-up
  
  By: Song P.H. , Kim Y.U. , Choi J.Y. , Ko Y.H. , Moon K.H. , Jung H.C.
  
  Institutes: College of Medicine, Yeungnam University, Dept. of Urology, Daegu, South Korea
  
  1083
  
  Surgeon tailored transobturator four arms mesh versus anterior colporrhaphy in the surgical management of cystocele accompanied by stress urinary incontinence
  
  To be confirmed
  
  1084
  
  Excision of symptomatic female urethral diverticulae: Outcomes in 121 cases utilising a modified prone jackknife position
  
  To be confirmed
  
  1085
  
  In vitro study of cellular, molecular and functional mechanisms underlying pelvic floor disorders
  
  To be confirmed
  
  1086
  
  Is the H line better than current reference lines for classifying anterior pelvic prolapse on magnetic resonance imaging?
  
  By: Rechi Sierra K. , Garcia Ibañez J. , Sánchez Ballester F. , Monzó Cataluña A. , Mitjana Biosca S. , Diranzo Garcia M. , Beltrán Puig M. , Juan Escudero J.U. , Povo Martín I.J. , Pardo Duarte P. , López Alzina E.
  
  Institutes: General University Hospital of Valencia, Dept. of Urology, Valencia, Spain
  
  1087
  
  Patient factors affect radiation exposure during video urodynamics
  
  To be confirmed
  
  1088
  
  Urethral pressure profile in women with voiding dysfunction – reproducibility and inter-observer error
  
  To be confirmed
  
  1089
  
  Are there differences in the urodynamic findings after laparoscopic sacrocolpopexy and Trocarless Transvaginal Mesh System for symptomatic pelvic organ prolapse?
  
  To be confirmed
  
  1090
  
  Large anesthetic bladder capacity is predictive of better response to hydrodistention in interstitial cystitis/bladder pain syndrome
  
  To be confirmed
  
  1091
  
  Does videourodynamic diagnosis of primary bladder neck obstruction in women predict success after bladder neck incision independent of detrusor pressure?
  
  To be confirmed
  
  1092
  
  Analysis of the correlation between the clinical effect of sacral neuromodulation and patients’ age — a retrospective, multicenter study in China
  
  By: Meng L. ¹ , Wei Z. ¹ , Yaoguang Z. ¹ , Jianye W. ¹ , Limin L. ² , Guoqing C. ² , Ling Q. ³ , Peng Z. ⁴ , Zhongqing W. ⁵ , Qi C. ⁶
  
  Institutes: ¹Beijing Hospital, Dept. of Urology, Beijing, China, ²China Rehabilitation Research Centre, Dept. of Urology, Beijing, China, ³Tongji Hospital, Huazhong University of Science and Technology, Dept. of Urology, Wuhan, China, ⁴Beijing Chaoyang Hospital, Dept. of Urology, Beijing, China, ⁵The Second Affiliated Hospital of Nanjing Medical University, Dept. of Urology, Nanjing, China, ⁶The Second Affiliated Hospital of Xi’an Jiaotong University, Dept. of Urology, Xi'an, China
16. Poster Session 67 - Radiotherapy for locally advanced and recurring prostate cancer
  
  Radiotherapy for locally advanced and recurring prostate cancer Poster Session 67
  
  15:45 - 17:15
  Radiotherapy for locally advanced and recurring prostate cancer
  
  Poster Session 67
  
  Sun 19 July
  15:45 - 17:15
  
  Location:
  
  Orange Area, eURO Auditorium 2
  
  Chairs:
  
  To be confirmed
  N.R. Suardi, Genoa (IT)
  To be confirmed
  
  Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.
  
  923
  
  Radiotherapy treatment for prostate cancer in Sweden: Patterns over 20 years
  
  By: Beckmann K. ¹ , Garmo H. ² , Van Hemelrijck M. ¹ , Nilsson P. ³ , Franck Lissbrant I. ⁴ , Stattin P. ⁵
  
  Institutes: ¹Kings College London, Dept. of Translational Oncology and Urology Research (TOUR), London, United Kingdom, ²Uppsala University Hospital, Regional Cancer Centre, London, United Kingdom, ³Skane University Hospital and Lund University, Dept. of Oncology and Radiation Physics, Lund, Sweden, ⁴University of Gothenburg, Sahlgrenska Academy, Gothenburg, Sweden, ⁵Uppsala University Hospital, Dept. of Surgical Sciences, Uppsala, Sweden
  
  924
  
  Increasing the age of brain: Effect of Androgen Deprivation Therapy (ADT) exposure on brain and cognition
  
  To be confirmed
  
  925
  
  Late toxicity and quality of life from GETUG-AFU 22 study: A randomized phase II trial comparing 6 months of degarelix in combination with radiotherapy to radiotherapy alone for patients with detectable PSA after radical prostatectomy
  
  To be confirmed
  
  926
  
  The oncologic outcomes of low-dose-rate brachytherapy for prostate cancer
  
  To be confirmed
  
  927
  
  IMRT by Helical Tomotherapy for prostate cancer increases the risk of bladder cancer at single institution
  
  To be confirmed
  
  928
  
  Radical Salvage Prostatectomy (RSP) for Radiorecurrent Prostate Cancer (rPCA): Onological and functional outcome of a large contemporary series
  
  By: Heidenreich A. ¹ , Shariat S. ² , Fahad Q. ² , Karnes J.R. ³ , Pfister D. ¹
  
  Institutes: ¹University Hospital Cologne, Dept. of Urology and Uro-Oncology, Cologne, Germany, ²University Hospital Vienna, Dept. of Urology, Vienna, Austria, ³Mayo Clinic, Dept. of Urology, Rochester, United States of America
  
  929
  
  Reliability of modern imaging studies for detection and final pathohistological stage in men undergoing radical salvage prostatectomy (RSP) for radiorecurrent prostate cancer (rPC)
  
  By: Heidenreich A. ¹ , Shariat S. ² , Fahad Q. ² , Karnes J.R. ³ , Pfister D. ¹
  
  Institutes: ¹University Hospital Cologne, Dept. of Urology and Uro-Oncology, Cologne, Germany, ²University Hospital Vienna, Dept. of Urology, Vienna, Austria, ³Mayo Clinic, Dept. of Urology, Rochester, United States of America
  
  930
  
  Salvage radical prostatectomy: Oncological outcomes from a large retrospective cohort study
  
  To be confirmed
  
  931
  
  Does salvage whole gland ablation therapy confer survival advantage to patients who failed primary radiotherapy for prostate cancer?
  
  By: Nair S.M. ¹ , Warner A. ² , Rodrigues G.B. ² , Chin J. ¹
  
  Institutes: ¹Western University, Dept. of Urology and Oncology, London, Canada, ²Western University, Dept. of Radiation Oncology, London, Canada
  
  932
  
  Early experience of salvage MRI guided transurethral ultrasound ablation for local prostate cancer recurrence after radiotherapy
  
  By: Anttinen M.H.J. ¹ , Mäkelä P. ² , Suomi V. ³ , Saunavaara J. ³ , Sainio T. ³ , Blanco R.S. ² , Taimen P. ⁴ , Boström P.J. ¹
  
  Institutes: ¹Turku University Hospital, Dept. of Urology, Turku, Finland, ²Turku University Hospital, Dept. of Radiology, Turku, Finland, ³Turku University Hospital, Dept. of Medical Physics, Turku, Finland, ⁴Turku University Hospital, Dept. of Pathology, Turku, Finland
  
  933
  
  Effectiveness of glycosaminoglycan replacement treatment with intravesical instillation in patients with haemorrhagic radiation cystitis post-pelvic radiotherapy
  
  By: Sanguedolce F. ¹ , Meneghetti J. ¹ , Montaño B. ¹ , Bevilacqua G. ¹ , Martinez C. ¹ , Saitta G. ¹ , Territo A. ¹ , Balaña J. ¹ , Gaya J.M. ² , Huguet J. ² , Palou Redorta J. ¹ , Breda A. ¹
  
  Institutes: ¹Fundacio Puigvert, Autonomous University of Barcelona, Dept. of Urology, Barcelona, Spain, ²Fundacio Puigvert, Dept. of Urology, Barcelona, Spain
  
  934
  
  Patients with biochemical recurrence after radical prostatectomy and local recurrence or negative PSMA PET/CT are excellent candidates for salvage radiotherapy to the prostatic fossa
  
  By: Luiting H.B. ¹ , Meijer D.* ² , Van Leeuwen P.J. ³ , Remmers S. ⁴ , Van Der Poel H.G. ³ , Witteveen T. ⁵ , Bodar Y.J.L ² , Oprea-Lager D.E. ⁶ , Jansen B.H.E. ² , Roobol M.J. ¹ , Vis A.N. ²
  
  Institutes: ¹Erasmus University Medical Center, Dept. of Urology, Rotterdam, The Netherlands, ²Amsterdam University Medical Center, Dept. of Urology, Amsterdam, The Netherlands, ³Netherlands Cancer Insitute, Dept. of Urology, Amsterdam, The Netherlands, ⁴Erasmus University Medical Center, Dept. of urology, Rotterdam, The Netherlands, ⁵Netherlands Cancer Insitute, Radiotherapy, Amsterdam, The Netherlands, ⁶Amsterdam University Medical Center, Radiology & Nuclear Medicine, Amsterdam, The Netherlands
  
  935
  
  EAU BCR risk classification as decision tool for salvage radiatiotherapy
  
  To be confirmed
  
  936
  
  Persistently elevated prostate-specific antigen after salvage lymph node dissection and its impact on long-term oncological outcomes. The importance of an extensive, multi-modal approach
  
  To be confirmed
  
  937
  
  Patterns of clinical recurrences after salvage lymph node dissection for lymph-node recurrent prostate cancer and their impact on oncological outcomes. The importance of patient stratification for tailored post-operative treatments
  
  To be confirmed
17. Poster Session 26 - Potential new techniques for the treatment of localised prostate cancer
  
  Potential new techniques for the treatment of localised prostate cancer Poster Session 26
  
  16:00 - 17:30
  Potential new techniques for the treatment of localised prostate cancer
  
  Poster Session 26
  
  Sat 18 July
  16:00 - 17:30
  
  Location:
  
  Orange Area, eURO Auditorium 2
  
  Chairs:
  
  M. Colombel, Lyon (FR)
  To be confirmed
  To be confirmed
  
  Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.
  
  342
  
  Benchmarking radical prostatectomy – analysis of the British Association of Urological Surgeons national database for radical prostatectomy
  
  To be confirmed
  
  343
  
  Ten years of experience in robot-assisted laparoscopic radical prostatectomy in brazil: Indirect evaluation of the perioperative costs and oncologic patients’ profiles
  
  To be confirmed
  
  344
  
  Comparison of learning curves with Da Vinci Standard/Si/Xi and single port robotic platform during radical prostatectomy: A single surgeon experience
  
  To be confirmed
  
  345
  
  Comparison of outcomes between single-port and standard robot-assisted radical prostatectomy at a large-volume center
  
  To be confirmed
  
  346
  
  Extraperitoneal versus transperitoneal single-port robotic radical prostatectomy: A comparative analysis of perioperative outcomes
  
  To be confirmed
  
  347
  
  Single-port suprapubic transvesical robotic assisted radical prostatectomy: Technique and outcomes
  
  To be confirmed
  
  348
  
  Robotic-assisted radical perineal prostatectomy (RAPP) – resurgence of a robust surgical treatment. Initial experience of 12 cases
  
  To be confirmed
  
  349
  
  Exogenous 5-aminolevulinic acid sensitizes prostate cancer cells to radiation therapy thorough mitochondria-mediated apoptosis induced by reactive oxygen species
  
  To be confirmed
  
  350
  
  A pilot transcriptomic analysis of archival prostate biopsy samples and response to radical radiotherapy
  
  To be confirmed
  
  351
  
  Automated Gleason grading of whole slide prostatectomy images
  
  To be confirmed
  
  352
  
  Accuracy of prostate cancer segmentation for 3D printing and modelling: A comparison between radiologists, urologists and scientists
  
  To be confirmed
  
  353
  
  A new quality control scoring system for multiparametric MRI of the prostate from the PRECISION trial
  
  By: Giganti F. ¹ , Kasivisvanathan V. ² , Punwani S. ¹ , Emberton M. ² , Allen C. ¹ , Moore C.M. ² , PRECISION Study Group
  
  Institutes: ¹University College London Hospital, Dept. of Radiology, London, United Kingdom, ²University College London Hospital, Dept. of Urology, London, United Kingdom
  
  354
  
  Ex-vivo experimental 7 Tesla high resolution magnetic resonance imaging of localized prostate cancer
  
  To be confirmed
  
  355
  
  Intraoperative fluorescence confocal microscopy of targeted biopsy cores for real time diagnosis of prostate cancer. Initial experience and results
  
  To be confirmed
  
  356
  
  Impact of surgical wait times during summer months on the oncological outcomes following robotic-assisted radical prostatectomy: 10 years’ experience from a large Canadian Academic Center
  
  To be confirmed
Green Area, Room 1
1. Urology beyond Europe - Joint Session of the European Association of Urology (EAU) and the Taiwan Urological Association (TUA)
  
  Joint Session of the European Association of Urology (EAU) and the Taiwan Urological Association (TUA) Urology beyond Europe
  
  09:45 - 12:15
  Joint Session of the European Association of Urology (EAU) and the Taiwan Urological Association (TUA)
  
  Urology beyond Europe
  
  Fri 17 July
  09:45 - 12:15
  
  Location:
  
  Green Area, Room 1
  
  Chairs:
  
  To be confirmed
  To be confirmed
2. Meeting of the EAU Section of Female and Functional Urology (ESFFU) in cooperation with the EAU Section of Urologists in Office (ESUO) - New registries, trials and authority regulations: How do they influence the practice of functional urologists?
  
  New registries, trials and authority regulations: How do they influence the practice of functional urologists? Meeting of the EAU Section of Female and Functional Urology (ESFFU) in cooperation with the EAU Section of Urologists in Office (ESUO)
  
  10:15 - 14:00
  New registries, trials and authority regulations: How do they influence the practice of functional urologists?
  
  Meeting of the EAU Section of Female and Functional Urology (ESFFU) in cooperation with the EAU Section of Urologists in Office (ESUO)
  
  Sat 18 July
  10:15 - 14:00
  
  Location:
  
  Green Area, Room 1
  
  Chair:
  
  To be confirmed
  
  Learning objectives
  
  The meeting will address several hot topics in functional urology: Management of male incontinence, the controversy involving synthetic slings for female stress incontinence, treatment options for LUTS in men including nocturia, recent advances in bladder pain syndrome, recurrent UTI in women and an up-date in neuro-urology, including bladder augmentation.
  
  10:15 - 10:18
  
  Introduction to the 1st ESFFU
  
  10:18 - 11:03
  
  Male incontinence
  
  Moderators :
  
  R. Hamid, London (GB)
  
  M. Drake, Bristol (GB)
  
  10:33 - 10:48
  
  Recent advances in male incontinence: The MASTER trial data
  
  To be confirmed
  
  10:48 - 11:03
  
  Male incontinence in difficult cases (irradiated, previous AUS, previous sling)
  
  To be confirmed
  
  10:18 - 10:33
  
  Is the ESFFU/EAU registry helping urologists to treat post-prostatectomy incontinence?
  
  To be confirmed
  
  11:03 - 11:58
  
  Debate Female stress urinary incontinence
  
  Moderators :
  
  To be confirmed
  
  E Costantini, Perugia (IT)
  
  Case presenter :
  
  E Costantini, Perugia (IT)
  
  11:08 - 11:23
  
  I prefer to maintain synthetic mid urethral sling as the first surgical option
  
  To be confirmed
  
  11:23 - 11:38
  
  Can we return to good old Burch colposuspension without educational programmes?
  
  K. Everaert, Ghent (BE)
  
  11:38 - 11:53
  
  Synthetic mid urethral slings and Burch colposuspension are not free of complications
  
  To be confirmed
  
  11:53 - 11:58
  
  Conclusions: Synthetic mid urethral sling or Burch colposuspension?
  
  To be confirmed
  
  11:58 - 12:13
  
  Treatment of recurrent urinary incontinence
  
  To be confirmed
  
  12:13 - 12:43
  
  ESFFU meets other societies
  
  Moderators :
  
  To be confirmed
  
  To be confirmed
  
  12:13 - 12:28
  
  International Continence Society (ICS) lecture: Has the paradigm of Botulinum Toxin A injection in the bladder wall for OAB changed?
  
  M.A. Averbeck, Porto Alegre (BR)
  
  12:28 - 12:43
  
  SUFU lecture: Interstitial cystitis: What have we learned so far from the Multidisciplinary Approach to the Study of Chronic Pelvic Pain (MAPP) research network?
  
  To be confirmed
  
  12:43 - 13:13
  
  ESFFU meets office urologists
  
  Moderators :
  
  To be confirmed
  
  G.R. Kasyan, Moscow (RU)
  
  12:43 - 12:58
  
  Management of nocturia in office practice
  
  A. Zachariou, Ioannina (GR)
  
  12:58 - 13:13
  
  Is persistent erectile dysfunction associated with 5ARIs a reality or a myth in daily practice?
  
  F. Dimitriadis, Kalamaria, Thessaloniki (GR)
  
  13:13 - 13:58
  
  Neuro-urology
  
  Moderators :
  
  T. Tarcan, Istanbul (TR)
  
  F. Van Der Aa, Leuven (BE)
  
  13:13 - 13:28
  
  Follow-up of the neuro-urological patient
  
  To be confirmed
  
  13:28 - 13:43
  
  Will the AnTIC trial change the way we manage patients on a CIC program?
  
  To be confirmed
  
  13:43 - 13:58
  
  Bladder augmentation after botulinum toxin failure: Tips and trics
  
  G.R. Kasyan, Moscow (RU)
  
  13:58 - 14:00
  
  Closing remarks
  
  To be confirmed
3. Thematic session 01 - Urinary reconstruction in (neuro)urology
  
  Urinary reconstruction in (neuro)urology Thematic session 01
  
  10:30 - 12:00
  Urinary reconstruction in (neuro)urology
  
  Thematic session 01
  
  Sun 19 July
  10:30 - 12:00
  
  Location:
  
  Green Area, Room 1
  
  Chairs:
  
  To be confirmed
  To be confirmed
  
  Learning objectives
  
  After the introduction of botulinum toxin A in the armamentarium of neurogenic bladder dysfunction, other more complex treatment options have been very much ignored. However Botulinum toxin does not work in every case. Advances in sacral neuromodulation have occurred and may prove useful for neurogenic patients. Urinary diversion may be a realistic option in complex cases, and urologists need to familiarize themselves with other neurological problems in addition to MS or SCI. Parkinson’s disease is a good example of a disease with multiple urological problems urologists that should be aware of.
  
  10:30 - 10:45
  
  State-of-the-art lecture Parkinson’s disease: What an urologist should know
  
  To be confirmed
  
  10:45 - 11:00
  
  State-of-the-art lecture Neurostimulation and neuromodulaton for SCI & MS: Out of sight out of heart?
  
  To be confirmed
  
  11:00 - 11:15
  
  State-of-the-art lecture New developments in neuromodulation
  
  To be confirmed
  
  11:15 - 11:30
  
  State-of-the-art lecture Long term FU of ureterosigmoidostomy for bladder exstrophy
  
  To be confirmed
  
  11:30 - 12:00
  
  Debate What happens if Botox does not work in MS anymore?
  
  11:30 - 11:35
  
  Case presentation
  
  To be confirmed
  
  11:35 - 11:45
  
  Go for surgery
  
  To be confirmed
  
  11:45 - 11:55
  
  Stay conservative
  
  G. Del Popolo, Florence (IT)
  
  11:55 - 12:00
  
  Summary
  
  To be confirmed
4. Thematic session 12 - The new EAU guidelines on Male Sexual and Reproductive Health: Challenges and controversies
  
  The new EAU guidelines on Male Sexual and Reproductive Health: Challenges and controversies Thematic session 12
  
  10:30 - 12:00
  The new EAU guidelines on Male Sexual and Reproductive Health: Challenges and controversies
  
  Thematic session 12
  
  Mon 20 July
  10:30 - 12:00
  
  Location:
  
  Green Area, Room 1
  
  Chairs:
  
  S.S. Minhas, London (GB)
  To be confirmed
  
  Learning objectives
  
  The previous and historical guidelines topics on sexual dysfunction, male infertility and hypogonadism have now been amalgamated into a single guidelines topic (SRH), with the specific aim to further develop the concept of men’s health. In this dedicated thematic session, the SRH guidelines group will present the new EAU guidelines on SRH. In particular the session will focus on novel and controversial areas in the new guidelines.
  
  10:30 - 10:35
  
  Introduction: A novel and evidence based approach for Men’s Health
  
  S.S. Minhas, London (GB)
  
  10:35 - 10:45
  
  Male hypogonadism: Who is the right candidate for TRT?
  
  To be confirmed
  
  10:45 - 11:00
  
  Erectile dysfunction: Is screening for cardio-vascular disease and endocrinopathies worthwhile?
  
  To be confirmed
  
  11:00 - 11:15
  
  Disorders of ejaculation: Do you need to screen for pathology?
  
  E.C. Serefoǧlu, Istanbul (TR)
  
  11:15 - 11:30
  
  Penile curvature and priapism: Medical vs. Surgical therapies
  
  To be confirmed
  
  11:30 - 11:45
  
  Male Infertility: Cancers, cardiovascular disease and surgery. Priming the urologist
  
  S.S. Minhas, London (GB)
  
  11:45 - 11:55
  
  Late effects, survivorship and the urologist
  
  To be confirmed
  
  11:55 - 12:00
  
  Questions and answers
  
  S.S. Minhas, London (GB)
5. Poster Session 34 - Urethral strictures: Timing, assessment of techniques and predictive factors for success and failure
  
  Urethral strictures: Timing, assessment of techniques and predictive factors for success and failure Poster Session 34
  
  12:15 - 13:45
  Urethral strictures: Timing, assessment of techniques and predictive factors for success and failure
  
  Poster Session 34
  
  Sun 19 July
  12:15 - 13:45
  
  Location:
  
  Green Area, Room 1
  
  Chairs:
  
  J.L.H.R. Bosch, Utrecht (NL)
  To be confirmed
  To be confirmed
  
  Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.
  
  453
  
  Evaluation of a collagen cell carrier for urethral reconstructive surgery using a biological simulation model
  
  To be confirmed
  
  454
  
  Serum testosterone is lower in non-idiopathic than in idiopathic anterior urethral strictures
  
  By: Puche-Sanz I. ¹ , Sabio-Bonilla A. ² , Sanchez-Conde V. ² , Vicente-Prados J. ² , Expósito M. ³ , Cózar-Olmo J.M. ¹
  
  Institutes: ¹Hospital Universitario Virgen de las Nieves. Inst Invest Biosanitaria Ibs Granada, Dept. of Urology, Granada, Spain, ²Hospital Universitario Virgen de las Nieves, Dept. of Urology, Granada, Spain, ³Fundación para la Investigación Biosanitaria de Andalucía Oriental (FIBAO), Dept. of Biostatistics, Granada, Spain
  
  455
  
  Does urethral rest with supra pubic catheter influence urethrographic results and surgical planning in urethral stricture patients?
  
  To be confirmed
  
  456
  
  Structural analysys of the bulbospongiosus muscle in patients with bulbar urethral strictures
  
  To be confirmed
  
  457
  
  Morphological factors enhancing the acceptance of buccal grafts in reconstructive urology
  
  To be confirmed
  
  458
  
  Withdrawn
  
  459
  
  Withdrawn
  
  460
  
  Withdrawn
  
  461
  
  Withdrawn
  
  462
  
  Urinary symptom non-response (“LUTS failure”) after urethroplasty: Incidence and associations
  
  To be confirmed
  
  463
  
  Outcomes of reconstruction following pelvic fracture urethral injury
  
  To be confirmed
  
  464
  
  The impact of pain and postoperative complications on outcome in patients treated with buccal mucosa graft urethroplasty – results of a randomized controlled study
  
  To be confirmed
  
  465
  
  How and for how long should patients be followed up after bulbar or bulbomembranous urethroplasty?
  
  To be confirmed
  
  466
  
  A multivariable analysis of preoperative factors predicting endoscopic recurrence of stricture after urethroplasty
  
  To be confirmed
  
  467
  
  Effectiveness of the endoscopic correction of vesicourethral anastomosis strictures after radical prostatectomy
  
  By: Keshishev N. , Serebryaniy S.A. , Polyakov N.V. , Sidiropoulos A.
  
  Institutes: N.A. Lopatkin Research Institute of Urology and Interventional Radiology, FSBI NMRRC of the Ministry of Health of Russia, Moscow, Russia
6. Poster Session 61 - Metastatic RCC: The impact of surgery
  
  Metastatic RCC: The impact of surgery Poster Session 61
  
  12:15 - 13:45
  Metastatic RCC: The impact of surgery
  
  Poster Session 61
  
  Mon 20 July
  12:15 - 13:45
  
  Location:
  
  Green Area, Room 1
  
  Chairs:
  
  O. Hakenberg, Rostock (DE)
  To be confirmed
  To be confirmed
  
  Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.
  
  * 834
  
  Nephrectomy after complete response to immune checkpoint inhibitors for metastatic Renal Cell Carcinoma (mRCC): A new surgical challenge?
  
  To be confirmed
  
  835
  
  Variations in the exposure to sunitinib with immediate and deferred cytoreductive nephrectomy (CN). A post-hoc analysis of the randomized controlled EORTC SURTIME trial
  
  By: Abu-Ghanem Y. ¹ , Van Thienen H. ² , Blank C. ² , Powles T. ³ , Collette L. ⁴ , Tombal B. ⁵ , Haanen J. ² , Bex A. ⁶
  
  Institutes: ¹Sheba Medical Centre, Dept. of Urology, Ramat-Gan, Israel, ²The Netherlands Cancer Institute, Dept. of Oncology, Amsterdam, The Netherlands, ³Barts Cancer Centre, Dept. of Oncology, London, United Kingdom, ⁴EORTC, Statistics, Brussels, Belgium, ⁵Catholic University Louvain, Dept. of Urology, Brussels, Belgium, ⁶The Netherlands Cancer Institute, Dept. of Urology, Amsterdam, The Netherlands
  
  836
  
  Performance of a new risk assessment tool for patients with metastatic renal cell carcinoma undergoing cytoreductive nephrectomy in the targeted therapy era: REMARCC score
  
  By: Mir Maresma M.C. ¹ , Marchioni M. ² , Campi R. ³ , Minervini A. ³ , Kriegmair M. ⁴ , Heck M. ⁵ , Porpiglia F. ⁶ , Van Bruwaene S. ⁷ , Linares E. ⁸ , Hevia V. ⁹ , Musquera M. ¹⁰ , Derweesh I. ¹¹ , Ghali F. ¹¹ , Autorino R. ¹² , Veccia A. ¹² , Roussel E. ¹³ , Albertsen M. ¹³ , Pavan N. ¹⁴ , Antonellia A. ¹⁵ , Palumbo C. ¹⁵ , Capitanio U. ¹⁶ , Klatte T. ¹⁷ , Erdem S. ¹⁸ , Rubio-Briones J. ¹⁹ , YAU Renal Cancer Group
  
  Institutes: ¹FUndacion Instituto Valenciano Oncologia, Dept. of Urology, Valencia, Spain, ²SS Annunziata Hospital, , Dept. of Urology, Chieti, Italy, ³University of Florence, Careggi Hospital, Florence, Italy., Dept. of Urology, Florence, Italy, ⁴University Medical Centre Mannheim, Mannheim, Germany, Dept. of Urology, Mannheim, Germany, ⁵Technical University of Munich, Munich, Germany, Dept. of Urology, Munich, Germany, ⁶School of Medicine, University of Turin-San Luigi Gonzaga Hospital, Dept. of Urology, Turin, Italy, ⁷AZ Groeninge, Dept. of Urology, Kortrijk, Belgium, ⁸Hospital La Paz, Dept. of Urology, Madrid, Spain, ⁹Hospital Ramon y Cajal, Dept. of Urology, Madrid, Spain, ¹⁰Hospital Clinic, Dept. of Urology, Barcelona, Spain, ¹¹UC San Diego Moores Cancer Center, University of California San Diego School of Medicine, Dept. of Urology, San Diego, United States of America, ¹²VCU Medical Center, Dept. of Urology, Richmond, United States of America, ¹³UKLeuven, Dept. of Urology, Leuven, Belgium, ¹⁴University of Trieste, Dept. of Urology, Trieste, Italy, ¹⁵Spedali Civili Hospital, University of Brescia, Dept. of Urology, Brescia, Italy, ¹⁶IRCCS Ospedale San Raffaele., Dept. of Urology, Milan, Italy, ¹⁷Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust, Dept. of Urology, Cambridge, United Kingdom, ¹⁸Istanbul University, Dept. of Urology, Istanbul, Turkey, ¹⁹Fundacion Instituto Valenciano Oncologia, Dept. of Urology, Valencia, Spain
  
  837
  
  Predictors for perioperative complications in cytoreductive nephrectomy: Analysis of the registry for metastatic RCC (REMARCC)
  
  By: Roussel E. ¹ , Campi R. ² , Minervini A. ² , Kriegmair M. ³ , Heck M. ⁴ , Klatte T. ⁵ , Kara Ö. ⁶ , Bertolo R. ⁷ , Erdem S. ⁸ , Capitanio U. ⁹ , Van Bruwaene S. ¹⁰ , Albersen M. ¹ , Linares E. ¹¹ , Antonelli A. ¹² , Rubio J. ¹³ , Pavan N. ¹⁴ , Autorino R. ¹⁵ , Derweesh I. ¹⁶ , Musqueara M. ¹⁷ , Hevia V. ¹⁸ , Porpiglia F. ¹⁹ , Ouzaid I. ²⁰ , Mir M.C. ¹³ , Young Academic Urologists Renal Cancer Working Group
  
  Institutes: ¹University Hospitals Leuven, Dept. of Urology, Leuven, Belgium, ²University of Florence, Dept. of Urology, Florence, Italy, ³University Medical Centre Mannheim, Dept. of Urology, Mannheim, Germany, ⁴Technical University of Munich, Dept. of Urology, Munich, Germany, ⁵Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust, Dept. of Urology, Bournemouth, United Kingdom, ⁶Kocaeli University, Dept. of Urology, Kocaeli, Turkey, ⁷San Carlo di Nancy, Dept. of Urology, Rome, Italy, ⁸Istanbul University, Dept. of Urology, Istanbul, Turkey, ⁹Ospedale San Raffaele, Dept. of Urology, Milan, Italy, ¹⁰AZ groeninge, Dept. of Urology, Kortrijk, Belgium, ¹¹Hospital La Paz, Dept. of Urology, Madrid, Spain, ¹²Spedali Civili Hospital, University of Brescia, Dept. of Urology, Brescia, Italy, ¹³Fundacion Instituto Valenciano Oncologia, Dept. of Urology, Valencia, Spain, ¹⁴University of Trieste, Dept. of Medical, Surgical and Health Science, Trieste, Italy, ¹⁵VCU Medical Center, Dept. of Urology, Richmond, United States of America, ¹⁶UC San Diego Moores Cancer Center, Dept. of Urology, San Diego, United States of America, ¹⁷Hospital Clinic, Barcelona, Dept. of Urology, Barcelona, Spain, ¹⁸Hospital Ramon y Cajal, Dept. of Urology, Madrid, Spain, ¹⁹University of Turin-San Luigi Gonzaga Hospital, Dept. of Urology, Turin, Italy, ²⁰University of Zielona Góra,, Dept. of Urology, Zielona Góra, Poland
  
  838
  
  The role of cytoreductive nephrectomy in the contemporary management of metastatic kidney cancer: Predictive factors for surgical complications and oncological survival
  
  By: Roussel E. ¹ , Verbiest A. ² , Milenkovic U. ¹ , Everaerts W. ¹ , Van Cleynenbreugel B. ¹ , Van Poppel H. ¹ , Joniau S. ¹ , Beuselinck B. ² , Devos G. ¹ , Muilwijk T. ¹ , Albersen M. ¹
  
  Institutes: ¹University Hospitals Leuven, Dept. of Urology, Leuven, Belgium, ²University Hospitals Leuven, Dept. of Medical Oncology, Leuven, Belgium
  
  839
  
  Lymph node dissection is associated with decreased survival and all cause mortality among patients undergoing cytoreductive nephrectomy for metastatic renal cell carcinoma
  
  To be confirmed
  
  840
  
  Minimally invasive versus open cytoreductive nephrectomy for primary metastatic renal cancer: A multi-institutional experience from the REMARCC registry
  
  By: Campi R. ¹ , Marchioni M. ² , Roussel E. ³ , Capitanio U. ⁴ , Klatte T. ⁵ , Kriegmair M. ⁶ , Erdem S. ⁷ , Rubio-Briones J. ⁸ , Minervini A. ¹ , Heck M. ⁹ , Porpiglia F. ¹⁰ , Van Bruwaene S. ¹¹ , Linares E. ¹² , Hevia V. ¹³ , Musquera M. ¹⁴ , Derweesh I. ¹⁵ , Autorino R. ¹⁶ , Pavan N. ¹⁷ , Antonelli A. ¹⁸ , Palumbo C. ¹⁸ , Guruli G. ¹⁶ , Ghali F. ¹⁵ , Amiel T. ⁹ , Mir M. ⁸ , YAU Renal Cancer Group
  
  Institutes: ¹University of Florence, Careggi Hospital, Dept. of Urology, Florence, Italy, ²SS Annunziata Hospital, Dept. of Urology, Chieti, Italy, ³KU Leuven , Dept. of Urology, Leuven, Belgium, ⁴IRCCS Ospedale San Raffaele, Dept. of Urology, Dept. of Oncology, Urological Research Institute, Milan, Italy, ⁵Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust, Dept. of Urology, Cambridge, United Kingdom, ⁶University Medical Centre Mannheim, Dept. of Urology, Mannheim, Germany, ⁷University of Istambul, Dept. of Urology, Istanbul, Turkey, ⁸Fundacion Instituto Valenciano Oncologia, Dept. of Urology, Valencia, Spain, ⁹Technical University of Munich, Dept. of Urology, Munich, Germany, ¹⁰University of Turin-San Luigi Gonzaga Hospital, Dept. of Urology, School of Medicine, Turin, Italy, ¹¹AZ Groeninge, Dept. of Urology, Kortrijk, Belgium, ¹²Hospital La Paz, Dept. of Urology, Madrid, Spain, ¹³Hospital Ramon y Cajal, Dept. of Urology, Madrid, Spain, ¹⁴Hospital Clinic, Dept. of Urology, Barcelona, Spain, ¹⁵UC San Diego Moores Cancer Center, University of California San Diego School of Medicine, Louisiana Jolla, Dept. of Urology, San Diego, United States of America, ¹⁶VCU Medical Center, Dept. of Urology, Richmond, United States of America, ¹⁷Surgical and Health Science, University of Trieste, Dept. of Urology, Trieste, Italy, ¹⁸Spedali Civili Hospital, University of Brescia, Dept. of Urology, Brescia, Italy
  
  841
  
  The impact of sarcomatoid features on survival outcomes in metastatic renal cell carcinoma patients receiving upfront cytoreductive nephrectomy: A retrospective analysis of a contemporary series
  
  By: Marchioni M. ¹ , Campi R. ² , Minervini A. ² , Klatte T. ³ , Kriegmair M. ⁴ , Erdem S. ⁵ , Capitanio U. ⁶ , Roussel E. ⁷ , Albertsen M. ⁷ , Heck M. ⁸ , Porpiglia F. ⁹ , Van Bruwaene S. ¹⁰ , Linares E. ¹¹ , Hevia V. ¹² , Musquera M. ¹³ , Derweesh I. ¹⁴ , Autorino R. ¹⁵ , Pavan N. ¹⁶ , Antonelli A. ¹⁷ , Rubio-Briones J. ¹⁸ , Vecchia A. ¹⁵ , Checcucci E. ⁹ , Claps F. ¹⁶ , Mir M.C. ¹⁸ , YAU Renal Cancer Group
  
  Institutes: ¹Department of Urology, SS Annunziata Hospital,, Dept. of Urology, Chieti, Italy, ²Department of Urology, University of Florence, Careggi Hospital, Florence, Italy., Dept. of Urology, Florence, Italy, ³Department of Urology, Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust, Bournemouth, UK., Dept. of Urology, Cambridge, United Kingdom, ⁴Department of Urology, University Medical Centre Mannheim, Mannheim, Germany, Dept. of Urology, Mannheim, Germany, ⁵Istanbul University, Istanbul Faculty of Medicine, Dept. of Urology, Istanbul, Turkey, ⁶Unit of Urology, Division of Oncology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy., Dept. of Urology, Milan, Italy, ⁷Department of Urology- UKLeuven, Leuven, Belgium, Dept. of Urology, Leuven, Belgium, ⁸Department of Urology, Technical University of Munich, Munich, Germany, Dept. of Urology, Munich, Germany, ⁹Department of Urology, School of Medicine, University of Turin-San Luigi Gonzaga Hospital, Turin, Italy, Dept. of Urology, turin, Italy, ¹⁰Department of Urology, AZ Groeninge, Kortrijk, Belgium, Dept. of Urology, Kortrijk, Belgium, ¹¹Department of Urology, Hospital La Paz, Madrid, Spain, Dept. of Urology, Madrid, Spain, ¹²Department of Urology, Hospital Ramon y Cajal, Madrid, Spain, Dept. of Urology, Madrid, Spain, ¹³Department of Urology, Hospital Clinic, Barcelona, Spain., Dept. of Urology, Barcelona, Spain, ¹⁴Department of Urology, UC San Diego Moores Cancer Center, University of California San Diego School of Medicine, Louisiana Jolla, California, USA, Dept. of Urology, San Diego, United States of America, ¹⁵Division of Urology, VCU Medical Center, Richmond, VA, USA, Dept. of Urology, Richmond, United States of America, ¹⁶Urology Clinic, Department of Medical, Surgical and Health Science, University of Trieste, Trieste, Italy, Dept. of Urology, Trieste, Italy, ¹⁷Department of Urology, Spedali Civili Hospital, University of Brescia, Brescia, ItalyAlessandro Antonelli, Dept. of Urology, Brescia, Italy, ¹⁸Fundacion Instituto Valenciano Oncologia, Dept. of Urology, Valencia, Spain
  
  842
  
  Proposal for a two-tier re-classification of stage IV/M1 renal cell carcinoma into M1 (oligometastatic) and M2 (polymetastatic) sub stages
  
  To be confirmed
  
  843
  
  Outcome after resection of isolated single- or oligometastatic lymph node metastases at the time of nephrectomy
  
  To be confirmed
  
  844
  
  Predictive factors for recurrence after complete metastasectomy in patients with metastatic renal cell carcinoma in the targeted therapy era
  
  By: Toshio T. , Fukuda H. , Ishihara H. , Yoshida K. , Kondo T. , Hirohito K. , Iizuka J. , Masayoshi O. , Ishida H. , Tanabe K.
  
  Institutes: Tokyo Women's Medical University, Dept. of Urology, Tokyo, Japan
  
  845
  
  The impact of metastasis location on overall survival among patients with renal cell carcinoma
  
  To be confirmed
  
  846
  
  Impact of metastasectomy on cancer specific and overall survival in metastatic renal cell carcinoma: Analysis of the REMARCC registry
  
  To be confirmed
  
  847
  
  Safety and efficacy of Cyberknife radiosurgery for visceral and lymph node metastases of renal cell carcinoma – a retrospective, single center analysis
  
  To be confirmed
7. Poster Session 10 - Prostate cancer: Occupational exposure, ethnicity and risk
  
  Prostate cancer: Occupational exposure, ethnicity and risk Poster Session 10
  
  12:30 - 14:00
  Prostate cancer: Occupational exposure, ethnicity and risk
  
  Poster Session 10
  
  Fri 17 July
  12:30 - 14:00
  
  Location:
  
  Green Area, Room 1
  
  Chairs:
  
  To be confirmed
  To be confirmed
  To be confirmed
  
  Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.
  
  * 117
  
  Ethnic variation in prostate cancer detection: A hypothesis generating study for use of the Stockholm3 test in an American cohort
  
  To be confirmed
  
  * 118
  
  Spironolactone use is associated with lower risk of prostate cancer
  
  By: Beckmann K. ¹ , Garmo H. ² , Lindahl B. ³ , Holmberg L. ¹ , Stattin P. ⁴ , Adolfsson J. ⁵ , Cruickshank K. ⁶ , Van Hemelrijck M. ¹
  
  Institutes: ¹Kings College London, Dept. of Translational Oncology and Urology Research (TOUR), London, United Kingdom, ²Uppsala University, Regional Cancer Center, Uppsala, Sweden, ³Uppsala University, Uppsala Clinical Research Center, Uppsala, Sweden, ⁴Uppsala University, Dept. of Surgical Sciences, Uppsala, Sweden, ⁵Karolinska Institutet, CLINTEC-Department, Stockholm, Sweden, ⁶Kings College London, Dept. of Nutritional Studies, London, United Kingdom
  
  * 119
  
  Occupational exposure and risk of genitourinary malignancies: A Canadian population study
  
  By: Nair S.M. ¹ , Luu Ly T. ² , Lavi A. ¹ , Sano Y. ² , Haan M. ² , Chin J. ¹ , Power N.E. ¹
  
  Institutes: ¹Western University, Dept. of Urology, Dept. of Surgery, London, Canada, ²Western University, Dept. of Sociology, London, Canada
  
  120
  
  Global variations in treatment decisions among men with localized prostate cancer: Patterns of care in 15,718 men from 9 countries
  
  To be confirmed
  
  121
  
  Withdrawn
  
  122
  
  Vitamin D level and mortality risk among Danish men with prostate cancer
  
  To be confirmed
  
  123
  
  Frequency of ejaculation: A factor associated with a higher risk of prostate cancer. CAPLIFE study
  
  By: Melgarejo Segura M.T. ¹ , Jimenez-Pacheco A. ¹ , Lozano-Lorca M. ² , Vazquez Alonso F. ³ , Arrabal-Polo M.A. ¹ , Sanchez-Tamayo J. ¹ , Arrabal-Martin M. ¹ , Jimenez-Moleon J.J. ² , Olmedo-Requena R. ²
  
  Institutes: ¹Hospital Universitario Clinico San Cecilio, Dept. of Urology, Granada, Spain, ²Granada University, Preventive Medicine and Health Public, Granada, Spain, ³Hospital Universitario Virgin de Las Nieves, Dept. of Urology, Granada, Spain
  
  124
  
  The effect of age on cancer-specific mortality in patients with prostate cancer: A population-based study across all stages
  
  To be confirmed
  
  125
  
  The deleterious association between proton pump inhibitors and prostate cancer-specific death – a population-based cohort study
  
  To be confirmed
  
  126
  
  Prostate cancer and Hispanic men: Unmasking the diversity and data
  
  To be confirmed
  
  127
  
  Cost-effectiveness of the diagnostic pathway for prostate cancer: Healthcare expenses, surgical and oncologic outcomes
  
  To be confirmed
  
  13:43 - 13:50
  
  Summary
  
  To be confirmed
8. EAU specialty session - EAU Patient Information Session: Urological Cancers - putting the patient first
  
  EAU Patient Information Session: Urological Cancers - putting the patient first EAU specialty session
  
  14:00 - 17:00
  EAU Patient Information Session: Urological Cancers - putting the patient first
  
  EAU specialty session
  
  Sun 19 July
  14:00 - 17:00
  
  Location:
  
  Green Area, Room 1
  
  Chairs:
  
  To be confirmed
  R.S. Greene, Amsterdam (NL)
  S. Sarikaya, Ankara (TR)
  To be confirmed
  
  Learning objectives
  
  This Patient Information Session addresses and brings into focus bladder-, kidney-, and prostate cancers together with patient’s experiences and needs, by welcoming a range of experts with diverse backgrounds.
  
  Learning objectives
  To explore aspects of bladder-, kidney-, and prostate cancer through various perspectives including Health Care Providers, Patient Advocacy Groups and Patients
  To examine the further-reaching impact on patients’ lives and their health care options.
  This session will include Q&A and open dialogue
  
  14:00 - 15:15
  
  Life after cancer treatment
  
  14:00 - 14:15
  
  Remote follow-up programme
  
  To be confirmed
  
  14:15 - 14:30
  
  Educational sessions for remote surveillance
  
  To be confirmed
  
  14:30 - 14:45
  
  We wish we knew then what we know now
  
  To be confirmed
  
  14:45 - 15:00
  
  Survivorship care: From the CanCon recommendations to the Mission on Cancer
  
  To be confirmed
  
  15:00 - 15:15
  
  Working with cancer: Restoring normality
  
  To be confirmed
  
  15:15 - 16:00
  
  Prostate cancer
  
  15:15 - 15:30
  
  Predictive individual risks of urinary incontinence after prostatectomy and impact on shared decision making
  
  To be confirmed
  
  15:30 - 15:45
  
  EUProms Study
  
  A. Deschamps, Antwerpen (BE)
  
  15:45 - 16:00
  
  ADT Educational Programme
  
  To be confirmed
  
  16:00 - 16:30
  
  Bladder cancer
  
  16:00 - 16:15
  
  Medicine shortage and recalls in bladder cancer
  
  To be confirmed
  
  16:15 - 16:30
  
  EVOLVE Study
  
  Speakers :
  
  J.E. Bjorkqvist, Aberdeen (GB)
  
  L. Makaroff, Chinnor (GB)
  
  16:30 - 17:00
  
  Kidney cancer
  
  16:30 - 16:45
  
  Kidney cancer follow-up
  
  To be confirmed
  
  16:45 - 17:00
  
  Meta-analysis of cancer patient engagement interventions in hard clinical outcomes
  
  R. Giles, Duivendrecht (NL)
9. Poster Session 71 - Innovations in translational research in renal cancer
  
  Innovations in translational research in renal cancer Poster Session 71
  
  14:00 - 15:30
  Innovations in translational research in renal cancer
  
  Poster Session 71
  
  Mon 20 July
  14:00 - 15:30
  
  Location:
  
  Green Area, Room 1
  
  Chairs:
  
  K. Junker, Homburg (DE)
  To be confirmed
  
  Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.
  
  * 982
  
  Transcriptomic characterization of renal cell carcinoma patients with progressive disease despite low initial risk of progression
  
  To be confirmed
  
  983
  
  Serum levels of the IL-33 decoy receptor soluble ST2; a possible prognostic marker in clear-cell renal cell carcinoma
  
  To be confirmed
  
  * 984
  
  Inhibition of SMYD2 suppresses tumor progression by down-regulating microRNA-125b and attenuates multi-drug resistance in renal cell carcinoma
  
  To be confirmed
  
  985
  
  Withdrawn
  
  * 986
  
  Therapeutic efficacy and tolerability of [225Ac]Ac-DOTA-hG250 targeted alpha therapy in a clear cell renal cell carcinoma mice model
  
  To be confirmed
  
  987
  
  VHL-HIF-2α axis-induced SMYD3 upregulation drives renal cell carcinoma progression via direct trans-activation of the epidermal growth factor receptor gene
  
  To be confirmed
  
  988
  
  Tumor-infiltrating TNFRSF9 positive CD8 T cells in renal cell carcinoma hold both exhaustion and effector phenotype and response better to immunotherapy
  
  To be confirmed
  
  989
  
  Exploration of urinary lipid biomarkers in patients with clear cell renal cell carcinoma
  
  To be confirmed
  
  990
  
  Transcriptomic correlates of non-enhancing tumor volume on imaging in clear cell renal cell carcinoma
  
  To be confirmed
  
  991
  
  Liquid biopsy in clear cell renal cell carcinoma: Urinary miR-210-3p as emerging specific biomarker
  
  To be confirmed
  
  992
  
  Emerging role of secreted urinary miR-210-3p as potential biomarker for clear cell renal cell carcinoma metastasis
  
  To be confirmed
  
  993
  
  TOX High Mobility Group Box Family Member 3 suppresses epithelial-mesenchymal transition in clear cell renal cell carcinoma by transcriptionally regulating SNAI1 and SNAI2
  
  To be confirmed
  
  15:17 - 15:24
  
  Summary
  
  K. Junker, Homburg (DE)
10. Poster Session 15 - Urethral strictures: The quest for the ultimate surgical solution
  
  Urethral strictures: The quest for the ultimate surgical solution Poster Session 15
  
  14:15 - 15:45
  Urethral strictures: The quest for the ultimate surgical solution
  
  Poster Session 15
  
  Fri 17 July
  14:15 - 15:45
  
  Location:
  
  Green Area, Room 1
  
  Chairs:
  
  To be confirmed
  L. Martínez Piñeiro, Madrid (ES)
  To be confirmed
  
  Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.
  
  186
  
  The versatility of the ventral approach to the bulbar urethra: Urethroplasty outcomes in a high volume UK tertiary referral centre
  
  By: Itam S. , Anderson P.C.B.
  
  Institutes: Russells Hall Hospital, Dept. of Genito-Urethral Reconstructive Urology, Dudley, United Kingdom
  
  187
  
  Interim analysis of the VeSpAR trial: A randomized controlled trial comparing Vessel-Sparing Anastomotic Repair and transecting anastomotic repair in isolated, short, bulbar urethral strictures
  
  By: Verla W. ¹ , Waterloos M. ¹ , Waterschoot M. ¹ , Van Parys B. ¹ , Suarez O. ² , Giudice C. ³ , Song L. ⁴ , Spinoit A. ¹ , Lumen N. ¹
  
  Institutes: ¹Ghent University Hospital, Dept. of Urology, Ghent, Belgium, ²Hospital San José Tecnologico de Monterrey, Dept. of Urology, Nuevo Léon, Mexico, ³Hospital Italiano de Buenos Aires, Dept. of Urology, Buenos Aires, Argentina, ⁴Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Dept. of Urology, Shanghai, China
  
  188
  
  Prospective randomized study to compare outcomes of ventral vs. dorsal onlay graft urethroplasty in female urethral stricture
  
  By: Katiyar V.K. , Goel H. , Sharma U. , Sood R.
  
  Institutes: ABVIMS and Dr Ram Manohar Lohia Hospital, Dept. of Urology and Renal transplant, New Delhi, India
  
  189
  
  Dorsal versus dorsolateral approach for buccal mucosal graft anterior urethroplasty: A prospective randomized study
  
  To be confirmed
  
  190
  
  Does aetiology of urethral stricture influence the survival of the buccal mucosa graft?
  
  To be confirmed
  
  191
  
  The role of one-stage buccal mucosal graft urethroplasty for secondary anterior urethral strictures following failed primary hypospadias repair: Long-term outcomes from a high volume referral center
  
  To be confirmed
  
  192
  
  A prospective analysis of patient-reported outcome measures after buccal mucosa graft urethroplasty for bulbar urethral strictures
  
  To be confirmed
  
  193
  
  Dorsal onlay buccal mucosa vs. vaginal-flap “Blandy” urethroplasty for female stricture: A single-center series
  
  To be confirmed
  
  194
  
  Is urethroplasty really more cost-effective than urethral dilatation for primary bulbar urethral strictures?
  
  To be confirmed
  
  195
  
  Mid-term results of anterior urethroplasty with tissue-engineered oral mucosa graft MukoCell®
  
  To be confirmed
  
  196
  
  Urethroplasty for post-radiation urethral strictures
  
  To be confirmed
  
  197
  
  Urethroplasty for failed hypospadias repair related strictures in adults: A retrospective analysis with long-term follow-up
  
  By: Verla W. , Van Nieuwenhuyse F. , Spinoit A. , Waterloos M. , Waterschoot M. , Hoebeke P. , Lumen N.
  
  Institutes: Ghent University Hospital, Dept. of Urology, Ghent, Belgium
  
  198
  
  Do reconstructive genitourinary sections really improve surgical outcomes? A comparative study between two different periods at an academic institution
  
  To be confirmed
  
  199
  
  Proposed algorithm for management of non-traumatic bulbar urethral strictures
  
  By: Chawla A.K. , Mohan A. , Kapadia A. , Kriplani A.
  
  Institutes: KMC Manipal, MAHE, Dept. of Urology and Renal Transplant, Manipal, India
  
  200
  
  Use of gracilis flap interposition in repair of urethrorectal fistulae, whether through a transperineal or transanal approach
  
  To be confirmed
11. Poster Session 20 - The iatrogenic blues of male stress incontinence, are we out of the dark ages?
  
  The iatrogenic blues of male stress incontinence, are we out of the dark ages? Poster Session 20
  
  14:15 - 15:45
  The iatrogenic blues of male stress incontinence, are we out of the dark ages?
  
  Poster Session 20
  
  Sat 18 July
  14:15 - 15:45
  
  Location:
  
  Green Area, Room 1
  
  Chairs:
  
  To be confirmed
  N. Thiruchelvam, Cambridge (GB)
  To be confirmed
  
  Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.
  
  255
  
  Bladder elevation in pelvic floor muscle training evaluated by cine MRI (magnetic resonance imaging) is associated with early recovery of continence after radical prostatectomy
  
  By: Shimura H. ¹ , Watanabe N. ² , Nakamura K. ² , Tsukamoto T. ² , Kuwahara Y. ² , Terada S. ³ , Mitsui T. ¹ , Takeda M. ¹
  
  Institutes: ¹Universtiy of Yamanashi, Dept. of Urology, Yamanashi, Japan, ²Nagakubo Hospital, Dept. of Urology, Tokyo, Japan, ³Medical Scaning Nippori, Dept. of Radiology, Tokyo, Japan
  
  256
  
  Urodynamic predictors of surgical outcomes following male sling implantation
  
  To be confirmed
  
  257
  
  Contemporary trends of radical prostatectomy and predictors for recovery of urinary continence in the elderly aged >70 years: Comparisons with the cohort aged ≤70 years
  
  To be confirmed
  
  258
  
  Management of moderate postprostatectomy stress urinary incontinence: A propensity score‐matching analysis comparing artificial urinary sphincter with fixed sling
  
  To be confirmed
  
  259
  
  Therapeutic efficacy of platelet-rich plasma in treatment of stress urinary incontinence due to intrinsic sphincter deficiency - which patients may benefit?
  
  To be confirmed
  
  260
  
  The first UK experience in using urethral bulking agents to treat men with stress urinary incontinence
  
  By: Yang B. , Foley S. , Britnell W.
  
  Institutes: Royal Berkshire Hospital, Dept. of Urology, Reading, United Kingdom
  
  261
  
  The role of external beam radiation therapy for post prostatectomy stress urinary incontinence in transobturator male sling outcomes. A multicentric experience
  
  To be confirmed
  
  262
  
  Retropubic versus transobturator Argus® adjustable male sling: Results from a multicenter study
  
  To be confirmed
  
  263
  
  AdVance XP® male sling in the treatment of post-prostatectomy stress incontinence: Updated-5-year data of a prospective multicentre study
  
  To be confirmed
  
  264
  
  Treatment of Post-Prostatectomy Incontinence (PPI) with non-obstructive Slings (n-oS). Results from a real life cohort of ideal and comorbid patients
  
  To be confirmed
  
  265
  
  AdVance (AdV) and AdVance XP (A-XP) slings, comparison of outcomes on ideal and non-ideal patients
  
  To be confirmed
  
  266
  
  Outcomes of Virtue® male sling for postprostatectomy incontinence
  
  To be confirmed
  
  267
  
  A single center study to evaluate the efficacy and safety of a new adjustable artificial urinary sphincter (VICTO): Follow-up >12 months
  
  By: Ameli G. , Weibl P. , Rutkowski M. , Hübner W.A.
  
  Institutes: Clinic of Korneuburg, Dept. of Urology, Korneuburg, Austria
  
  268
  
  5 year experience on the Adjustable Transobturator Male System (ATOMS) in UK men with stress urinary incontinence®
  
  By: Yang B. , Kowalski P. , Jelley C. , Foley S.
  
  Institutes: Royal Berkshire Hospital, Dept. of Urology, Reading, United Kingdom
  
  269
  
  Prospective registry for patients undergoing surgery for male stress urinary incontinence in multiple European centres. an update of the registry ‘SATURN’
  
  By: Van Der Aa F. ¹ , Heesakkers J. ² , Martens F. ² , Nilsen O.J. ³ , Zachoval R. ⁴ , De Kort L. ⁵ , Romero Otero J. ⁶ , Thiruchelvam N. ⁷ , Bjartell A. ⁸ , Caris C. ⁸ , Schipper R. ⁸ , Witjes W. ⁸ , Hamid R. ⁹
  
  Institutes: ¹University Hospitals Leuven, Dept. of Urology, Leuven, Belgium, ²Radboud UMC, Dept. of Urology, Nijmegen, The Netherlands, ³Oslo University Hospital, Dept. of Urology, Oslo, Norway, ⁴Thomayer Hospital, Dept. of Urology, Prague, Czech Republic, ⁵UMC Utrecht, Dept. of Urology, Utrecht, The Netherlands, ⁶University Hospital 12 de Octubre, Dept. of Urology, Madrid, Spain, ⁷Addenbrooke's Hospital, Dept. of Urology, Cambridge, United Kingdom, ⁸EAU Research Foundation, Central Research Office, Arnhem, The Netherlands, ⁹Royal National Orthopaedic Hospital, Dept. of Urology, London, United Kingdom
12. Poster Session 27 - Female stress urinary incontinence: Surgical management
  
  Female stress urinary incontinence: Surgical management Poster Session 27
  
  16:00 - 17:30
  Female stress urinary incontinence: Surgical management
  
  Poster Session 27
  
  Sat 18 July
  16:00 - 17:30
  
  Location:
  
  Green Area, Room 1
  
  Chairs:
  
  To be confirmed
  To be confirmed
  
  Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.
  
  357
  
  Prevalence and trends in urinary incontinence among adult women in the United States 2005-2016
  
  To be confirmed
  
  * 358
  
  Litoxetine (LTX) shows significant treatment effect in urinary incontinence (UI)
  
  To be confirmed
  
  359
  
  Novel MRI-based evaluation of urinary sphincter function by diffusion tensor imaging to differentiate between rest and contraction
  
  To be confirmed
  
  360
  
  Clinical and urodynamic findings in women affected by mixed urinary incontinence
  
  To be confirmed
  
  361
  
  Predictors of outcomes after the anti-incontinence procedure in female with equal severity for stress and urge urodynamic mixed urinary incontinence
  
  To be confirmed
  
  362
  
  Identify women undergoing surgery for SUI who will benefit most of a single incision sling
  
  By: Van Der Aa F. ¹ , Capon G. ² , Ryckebusch H. ³ , Ferry P. ⁴
  
  Institutes: ¹UZ Leuven, Dept. of Functional and Reconstructive Urology, Neurourology, Leuven, Belgium, ²Pellegrin hospital, Dept. of Urology, Bordeaux, France, ³Coloplast, Medical Affairs Office, Le Plessis - Robinson, France, ⁴Saint Louis Hospital, Dept. of Gynaecology, La Rochelle, France
  
  363
  
  Interim analysis of a European prospective observational study evaluating patient reported outcomes of Altis single incision sling in women operated for stress urinary incontinence
  
  To be confirmed
  
  364
  
  Long-term outcomes from TVT procedures for treatment of female stress urinary incontinence: Data from a minimum of 18 years of follow-up
  
  By: Song P.H. , Kim Y.U. , Choi J.Y. , Ko Y.H. , Moon K.H. , Jung H.C.
  
  Institutes: College of Medicine, Yeungnam University, Dept. of Urology, Daegu, South Korea
  
  365
  
  Correlation of presenting symptoms with explanted synthetic mid-urethral sling pathology findings
  
  To be confirmed
  
  366
  
  Preliminary results of midurethral synthetic tape with tension control mechanism in comparison with conventional tape for female urinary stress incontinence: A randomized controlled trial
  
  To be confirmed
  
  * 367
  
  Development and investigation of a tissue-engineered biodegradable mesh for the treatment of Stress Urinary Incontinence (SUI) in female patients
  
  To be confirmed
  
  368
  
  Robot-assisted artificial urinary sphincter implantation in female patients: An international multicenter study
  
  To be confirmed
  
  369
  
  Outcomes of laparoscopic artificial urinary sphincter in women with stress urinary incontinence
  
  To be confirmed
  
  370
  
  Real-life outcomes after artificial urinary sphincter explantation in women suffering from severe stress incontinence
  
  To be confirmed
Green Area, Room 2
1. Video Session 01 - Emerging technologies in partial nephrectomy
  
  Emerging technologies in partial nephrectomy Video Session 01
  
  09:00 - 10:30
  Emerging technologies in partial nephrectomy
  
  Video Session 01
  
  Fri 17 July
  09:00 - 10:30
  
  Location:
  
  Green Area, Room 2
  
  Chairs:
  
  A. Mottrie, Aalst (BE)
  To be confirmed
  To be confirmed
  
  All presentations have a maximum length of 8 minutes, followed by 4 minutes of discussion.
  
  09:00 - 09:03
  
  Introduction
  
  V001
  
  Beyond the limits of ultrasound: Three dimensional augmented reality robot assisted partial nephrectomy (3D AR-RAPN) for complex renal masses
  
  By: Porpiglia F. ¹ , Checcucci E. ¹ , Amparore D. ¹ , Piramide F. ¹ , Volpi G. ¹ , De Cillis S. ¹ , Verri P. ¹ , Manfredi M. ¹ , Piazzolla P. ² , Fiori C. ¹ , Vezzetti E. ² , Mottrie A. ³
  
  Institutes: ¹AOU San Luigi Gonzaga, Dept. of Urology, Orbassano, Italy, ²Politecnico di Torino, Dept. of Management and Production Engineering, Turin, Italy, ³OLV Hospital, Dept. of Urology, Aalst, Belgium
  
  V002
  
  Nephron sparing surgery in patients with extension of renal cell carcinoma to the main renal vein: Intrarenal and extrarenal thrombectomy
  
  To be confirmed
  
  V003
  
  Transarterial ICG delivery before purely off-clamp robot-assisted partial nephrectomy for totally endophytic renal tumors: Technique and outcomes
  
  To be confirmed
  
  V004
  
  Robot assisted partial nephrectomy for hilar tumors: Technique, perioperative, oncologic and functional outcomes from a single center series
  
  To be confirmed
  
  V005
  
  Laparoscopic partial nephrectomy with intra-arterial hypothermic perfusion
  
  By: Ajami Fardoun T. , Martos R. , D'Anna M. , Mercader C. , Sierra A. , Alcaraz A.
  
  Institutes: Hospital Clinic de Barcelona, Dept. of Urology, Barcelona, Spain
  
  V006
  
  Purely off-clamp robot-assisted partial nephrectomy for totally endophytic renal tumors: Mid-term outcomes from a single-center series
  
  To be confirmed
  
  V007
  
  Withdrawn
  
  10:22 - 10:27
  
  Closing remarks
2. Meeting of the EAU Section of Infections in Urology (ESIU) - The threat of urogenital infections
  
  The threat of urogenital infections Meeting of the EAU Section of Infections in Urology (ESIU)
  
  10:15 - 14:00
  The threat of urogenital infections
  
  Meeting of the EAU Section of Infections in Urology (ESIU)
  
  Sat 18 July
  10:15 - 14:00
  
  Location:
  
  Green Area, Room 2
  
  Chairs:
  
  To be confirmed
  To be confirmed
  
  10:15 - 10:20
  
  Welcome and introduction
  To be confirmed
  To be confirmed
  
  10:20 - 11:25
  
  Urgent update for urologists: Fluoroquinolones in urology – Where do we stand?
  
  Moderators :
  
  To be confirmed
  
  To be confirmed
  
  10:20 - 10:35
  
  The standpoint of the European Medicines Agency (EMA) regarding the use of fluoroquinolones
  
  To be confirmed
  
  10:35 - 11:05
  
  Legal consequences on the use of fluoroquinolones - Case reports and lawyers view
  
  B. Leigh, London (GB)
  
  10:35 - 11:05
  
  To be confirmed
  
  10:35 - 11:05
  
  To be confirmed
  
  11:05 - 11:20
  
  Antibiotic prophylaxis in prostate biopsy – What are the alternatives?
  
  To be confirmed
  
  11:20 - 11:25
  
  Discussion
  
  11:25 - 12:25
  
  Complicated urinary tract infections
  
  Moderators :
  
  To be confirmed
  
  K. Naber, Straubing (DE)
  
  11:25 - 11:40
  
  Complicated and uncomplicated UTIs – Is it still a valid classification?
  
  To be confirmed
  
  11:40 - 11:55
  
  New antibiotics for complicated UTI/pyelonephritis
  
  To be confirmed
  
  11:55 - 12:25
  
  Panel discussion Nightmare cases – When even the experts are in trouble - What is the lawyers perspective?
  
  Panel :
  
  B. Leigh, London (GB)
  
  To be confirmed
  
  12:25 - 13:00
  
  Therapy and prophylaxis in recurrent UTI
  
  Moderators :
  
  To be confirmed
  
  To be confirmed
  
  12:25 - 12:35
  
  Host-pathogen interactions in UTIs and their implications in clinical medicine
  
  To be confirmed
  
  12:35 - 12:45
  
  Urine tests vs. patient’s symptoms – What should we use for diagnosis?
  
  To be confirmed
  
  12:45 - 12:55
  
  Management of recurrent UTIs according to the EAU Guidelines
  
  To be confirmed
  
  12:55 - 13:00
  
  Discussion
  
  13:00 - 13:59
  
  Prudent antibiotic use - Antibiotic stewardship - Urosepsis
  
  Moderators :
  
  To be confirmed
  
  E. Kulchavenya, Novosibirsk (RU)
  
  13:00 - 13:15
  
  Reduction of inappropriate use of catheters
  
  S.E. Geerlings, Amsterdam (NL)
  
  13:15 - 13:25
  
  How to prevent surgical site infections and postoperative infections?
  
  To be confirmed
  
  13:25 - 13:35
  
  Urosepsis and the role of antimicrobial stewardship programmes
  
  To be confirmed
  
  13:35 - 13:55
  
  Optimal management of urosepsis
  
  To be confirmed
  
  13:55 - 13:59
  
  Discussion
  
  13:59 - 14:00

Grey Area, Room G105

Grey Area, Room G105

Orange Area, eURO Auditorium 1

Orange Area, eURO Auditorium 2

Green Area, Room 1

Green Area, Room 2

Green Area, Room 3

Green Area, Room 4

Green Area, Room 5

Purple Area, Room Elicium 1

Purple Area, Room Elicium 2

Grey Area, RAI Auditorium

Yellow Area, Room Forum

Grey Area, Room Emerald

Yellow Area, Room E102

Yellow Area, Room E103

Green Area, Room A

Green Area, Room B

Grey Area, Room G102

Grey Area, Room G103

Grey Area, Room G104

Grey Area, Room G105

Grey Area, Room G106

Grey Area, Room G107

Grey Area, Room G108

Grey Area, Room G109

Grey Area, Room G002

Grey Area, Room G004

Orange Area, Room 1

Orange Area, eURO Auditorium 1

Orange Area, eURO Auditorium 2

Green Area, Room 1

Green Area, Room 2